Published in final edited form as:

Chem Rev. 2016 October 26; 116(20): 12688–12710. doi:10.1021/acs.chemrev.6b00296.

The Functions and Malfunctions of AID/APOBEC Family Deaminases: the known knowns and the known unknowns

Sachini Siriwardena¹, Kang Chen^{2,3,4}, and Ashok S. Bhagwat^{1,4}

¹Department of Chemistry, Wayne State University, Detroit, MI 48202

²Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201

³Mucosal Immunology Studies Team, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892

⁴Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, MI 48201

Abstract

The AID/APOBEC family enzymes convert cytosines in single-stranded DNA to uracil causing base substitutions and strand breaks. They are induced by cytokines produced during the body's inflammatory response to infections, and help combat infections through diverse mechanisms. AID is essential for the maturation of antibodies and causes mutations and deletions in antibody genes through somatic hypermutation (SHM) and class-switch recombination (CSR) processes. One member of the APOBEC family, APOBEC1, edits mRNA for a protein involved in lipid transport. Members of the APOBEC3 subfamily in humans (APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G and APOBEC3H) inhibit infections of viruses such as HIV, HBV and HCV, and retrotransposition of endogenous retroelements through mutagenic and non-mutagenic mechanisms. There is emerging consensus that these enzymes can cause mutations in the cellular genome at replication forks or within transcription bubbles depending on the physiological state of the cell and the phase of the cell cycle during which they are expressed. We describe here the state of knowledge about the structures of these enzymes, regulation of their expression, and both the advantageous and deleterious consequences of this expression including carcinogenesis. We highlight similarities among them and present a holistic view of their regulation and function.

TOC image

1. Introduction

Activation-induced deaminase (AID) and apolipoprotein B mRNA-editing catalytic polypeptide-like (APOBEC) proteins are found in all tetrapods including the primates and in bony fish including the lampreys. They deaminate cytosine to uracil in single-stranded DNA (ssDNA)^{1–6} or in both ssDNA and RNA.^{5,7–9} Primates appear to have the highest number of this family of proteins¹⁰ and in humans they include AID, APOBEC1, APOBEC2, seven APOBEC3 subfamily members (APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G and APOBEC3H) and APOBEC4¹¹. In this review we will principally discuss the biochemical properties and biological functions of the mammalian AID/APOBEC family proteins, with the exception of APOBEC2 and APOBEC4. The latter two proteins appear not to be catalytically active and will not be discussed here.

These enzymes are part of the cellular innate and adaptive immune response that protects the host organism against infection. Although the biochemical properties of these enzymes will be described below, the principal focus of this review is to summarize what is known about their biological functions. The important immunological functions of these enzymes come with the potential risk of causing considerable damage to the host genome and we will review what is known about the harmful effects of these enzymes in mammalian cells and in humans. A major goal of this review is to identify the gaps in our understanding of these enzymes. Consequently, the review will highlight the limitations of the available data and the inadequacies of the tools of study or biological models.

Most recent reviews have treated AID, APOBEC1 and APOBEC3 proteins as if they were unrelated, and have not emphasized the functional overlaps between them. Here, we will identify similarities between them and try to integrate what is known about these enzymes to create a coherent narrative. In particular, we will outline how the regulation of AID overlaps with that of the APOBEC3 enzymes during the inflammatory response to an infection, and suggest a model of how the biological functions of these enzymes go hand in hand with their ability to cause cellular malfunction.

2. Biochemical properties of AID/APOBEC proteins

AID/APOBEC proteins have a characteristic zinc-coordination motif (H-X-E-X₂₃₋₂₈-P-C-X-C) within the active site where a water molecule binds Zn²⁺ and the metal ion is coordinated by one histidine and two cysteines.¹² While the genes for AID, APOBEC1 (A1), APOBEC3A (A3A), APOBEC3C (A3C) and APOBEC3H (A3H) contain a single Zn²⁺-binding domain, genes for APOBEC3B (A3B), APOBEC3D/E (A3D/E), APOBEC3F (A3F) and APOBEC3G (A3G) have resulted from duplications of the primordial gene^{10,13} and contain two putative zinc-binding motifs. In all cases where there are two Zn²⁺-binding domains, only the carboxy-terminal domain is catalytically active. Based on prior work with bacterial and yeast cytidine deaminases, it has been suggested that a conserved glutamate plays a central role in catalysis by shuttling a proton between the bound water molecule and N3 of cytosine, and between the resulting ⁻OH and the exocyclic amino group of cytosine.¹² They show little activity towards the free cytosine base, its nucleosides or mononucleotides.^{1,4}

Different AID/APOBEC proteins deaminate cytosines in different preferred sequence contexts. They have a stronger preference for specific bases on the 5' side of the target cytosine than on its 3' side. While AID prefers WRC¹⁴ (W is A or T, R is purine, target cytosine is underlined) sequence, APOBEC3G prefers CCC, and the other family members target YC sequences (Y is pyrimidine) with a preference for T as the pyrimidine.^{1,15}

APOBEC2 was the first member of the family for which the crystal structure became available¹⁶ and subsequently the structures of several APOBEC3 subfamily proteins have been determined. The structures have been determined for A3A^{17,18}, A3C¹⁹ and the C-terminal catalytic domains of A3B and A3F.²⁰⁻²² Additionally, several structures of the C-terminal domain of APOBEC3G (A3G-CTD) have been reported based on X-ray crystallographic and NMR studies.²³⁻²⁵ As yet, the complete structure of a two Zn²⁺-domain member of the APOBEC3 subfamily has not been reported.

Using ENDscript 2 software²⁶ we compared representative APOBEC3 subfamily structures and identified their common structural elements (Fig. 1A). The proteins share extensive secondary structural similarity reflecting their sequence similarities and their tertiary structure has a central β sheet surrounded by three helices on each side. The principal difference between the different structures is that while A3F, A3C and A3A have a continuous β 2 strand, this strand is interrupted by an α helix or a β turn in A3B and A3G structures (Fig. 1A). The biochemical consequences of this difference are unclear. The active site Zn²⁺ is coordinated by one His and two Cys residues and these residues are at the edges of two helices that lie close to the surface of the protein (Figs. 1A and 1B). Coulombic surface potential map of A3F-CTD²⁷ shows that the catalytic center is near a cavity with negative potential and this is likely to be the pocket in which the target cytosine is inserted. There is no groove with a strong positive potential on the protein surface near the catalytic center for nucleic acid binding. Instead, there is a surface patch of neutral/positive potential that extends from the catalytic residues towards loop 7 (Fig. 1B). This may interact with the substrate DNA and two potential paths for the DNA are shown in Figure 1B.

A number of independent lines of evidence show that the principal determinant of DNA sequence specificity within the AID/APOBEC proteins is the loop 7 (Fig. 1B). This conclusion is supported by experiments in which loop 7 was exchanged between different members of the family resulting in the swapping of sequence specificities.^{28–30} Additionally, replacement of loop 7 in AID with the corresponding sequence in A3A resulted in increased preference for methylated cytosines for deamination that is characteristic of A3A.⁸ Molecular docking of a single-stranded DNA template with A3A also suggested interaction between several residues in loop 7 with DNA with additional interactions with loops 1, 3 and 5.³¹ Alanine scanning mutagenesis of loop 7 in AID revealed several residues essential for deamination activity.³² Saturation mutagenesis of loop 7 residues in AID followed by multiple rounds of genetic selection for cytosine deamination confirmed this result.³² In other experiments, D317 in this loop of A3G was substituted with tyrosine resulting in the changing of the sequence-specificity of the enzyme from 5'-CC to 5'-YC.³³ Mutational studies of A3F also showed that a replacement of W310 in this loop with alanine resulted in decreased binding to DNA and reduced deaminase activity.³⁴ NMR studies of interactions between deoxynucleotides or ssDNA with A3A showed that residues in the loop 7 interact with nucleotides on either side of the target cytosine.¹⁷ Together these studies show that while loop 7 is the principal determinant of sequence specificity in AID/APOBEC enzymes, loops 1, 3 and 5 also contribute to DNA binding.^{28,35,36} A more complete picture of the mechanism of DNA sequence recognition will emerge when structures of enzyme-DNA co-crystals become available.

Despite extensive studies, the subunit composition of these enzymes is poorly understood and remains controversial. The multimerization of these proteins *in vitro* has been studied using a large number of biochemical and biophysical techniques including co-immunoprecipitation, yeast two-hybrid analysis, bimolecular fluorescence complementation, size exclusion chromatography, matrix-assisted laser desorption ionization time-of-flight spectrometry, small angle X-ray scattering, X-ray crystallography, nuclear magnetic resonance, density gradient separation of cytoplasmic components, atomic force microscopy as well as through studies of live and fixed cells.^{17,20,37–47} Based on such studies a variety of different subunit compositions have been reported for most of the proteins. A3G has been studied most extensively in this regard and the data collectively suggest that A3G can be present as a monomer, dimer, tetramer or an oligomer, and the process of oligomerization may depend on protein modifications, intracellular protein concentration, salt conditions, presence of RNA, presence of HIV-1 infectivity factor, Vif (see below), subcellular localization and the cell type in which it is expressed. This makes it difficult to correlate multimerization of this and other proteins in the family with their biological function.

APOBEC1 (A1) is known to cause C to U conversion in mRNA⁷, but it can also act on cytosines in single-stranded DNA.⁴⁸ The RNA editing by A1 in the mammalian apolipoprotein B gene creates a termination codon that shortens the resulting protein with altered function.⁴⁹ The function of its DNA editing ability is not known. AID is required for the creation of high affinity antibodies against antigens. It causes mutations in the immunoglobulin genes and facilitates “maturation” of antibodies following an infection.⁵⁰ The biological function of APOBEC3 subfamily proteins is to introduce mutations in the genome of viruses infecting cells or within endogenous retroelements during

retrotransposition.^{51,52} APOBEC2 and APOBEC4 will not be discussed further because they do not show any deaminase activity and their functions remain poorly defined.

3. Activation-induced deaminase (AID)

The biological function of AID in adaptive immunity is well understood, but the biochemical pathways it participates in remain poorly understood at the molecular level. In particular, the steps downstream of AID action on DNA do not fit our understanding of DNA repair pathways and it appears that AID colludes with DNA repair pathways to rearrange the genomes of B lymphocytes and alter their genetic information. It is a major challenge to understand how the enzymes in base-excision repair (BER) and mismatch repair (MMR) cause high levels of mutations and strand breaks with the help of AID, when several decades of studies have shown that these pathways have evolved to protect the genome. Finally, it would be naïve to think that the damage done by AID to the genome can be restricted to the immunoglobulin loci. Increasingly, it is becoming clear that cytosines outside the immunoglobulin genes are targets of AID and that this is a source of mutations and genome instability in B lymphocytes and other cells.

3.1 Somatic hypermutation

The maturation of antibodies occurs in B cells when they enter transient structures called germinal centers that form within peripheral lymphoid organs. AID causes hypermutations in the “variable region” of antibody genes, resulting in an increase in the affinity of antibodies for antigens. This process is called somatic hypermutation (SHM). During their maturation process, the antibodies are transported to the surface of B lymphocytes and act as receptors, and the ability of these B cell receptors to bind an antigen and interact with follicular helper T cells assures their survival and proliferation. This is called clonal selection^{53–55} and repeated cycling of B cells through a process of hypermutation and selection is responsible for a time-dependent increase in the affinity of antibodies for antigens derived from an infectious agent.^{56–58}

Prior to an infection, combinatorial reassortment of variable (V), diversity (D) and junction (J) segments generates millions of unique combinations in different cells and creates the V(D)J exon in the immunoglobulin (Ig) gene. The vertebrate B lymphocytes acquire hypermutations in a region that includes the V(D)J exon either through a process that involves damage to DNA followed by error-prone repair (SHM; Fig. 2) or gene conversion (GC) between V(D)J and upstream pseudo-V segments.⁵⁹ AID is required for both these processes.^{50,60,61} GC of Ig genes is not observed in humans and will not be discussed here.

The variable region of the Ig gene is approximately 1,500 base pair (bp) long and extends from about 150 bp downstream of the Ig promoters to the beginning of the intron separating V(D)J from the constant domain exons (Fig. 2). The mutations caused by AID include all transitions and transversions and generally occur at a rate of about 10^{-3} per bp per generation. About 30% of the mutations are found in the two hotspots 5'-RGYW/5'-WRCY (W is A or T, R is purine and Y is pyrimidine) and TTA/TAA⁶² and show a roughly bell-shaped distribution over the region. There is no detectable strand bias in the mutations,

suggesting that the mutational process acts on both the template and the coding strand of the gene.

As the sequence selectivity of purified AID is WRC¹⁴, and hence the principal hotspot for SHM, RGYW/WRCY⁶³, may be solely determined by this selectivity. However, a copying of uracils generated by AID results in only C:G to T:A transitions and other types of base substitutions found in SHM are caused by translesion synthesis (TLS) polymerases. In this model⁶⁴, error-prone repair of uracils results in the creation of any of the three possible base substitutions (Fig. 3A). UNG2 excises the uracil creating an abasic (AP) site and TLS polymerases insert any of the four bases across the AP site. TLS polymerase η would predominantly insert an adenine across the AP site causing C:G to T:A mutation⁶⁵, but other TLS polymerases may insert other bases across the AP site expanding the spectrum of mutations. For example, REV1 inserts C across an AP site^{66,67} and would create C:G to G:C transversions. This model further suggests that the actions of MMR and UNG2 help extend the mutations to the base pairs flanking the target cytosine^{64,68,69}, but the mechanistic details of this process are unclear. Together, these processes spread the mutations outside the WRC sites that are the targets of AID for deamination and allow the creation of all six base substitution mutations. The roles of TLS polymerases Pol η and REV1 in shaping the mutation spectrum in SHM has been reviewed in greater detail elsewhere.^{70–72}

SHM requires transcription of the target sequences^{73,74} and this topic was reviewed recently.⁷⁵ There are good biochemical reasons why AID is likely to act at transcription pause or arrest sites. Transcription causes separation of DNA strands potentially exposing them to AID. However, AID is a slow enzyme (rate of deamination of 0.03 sec⁻¹)^{76–78}, and hence cannot capture cytosines in a transcription bubble that normally stays open for about 0.1 sec during normal elongation.⁷⁹ Thus, AID is much more likely to find cytosines in ssDNA at a pause or arrest site than within a transcript elongation complex.⁸⁰

Many structural and mechanistic aspects of the interaction between AID and the transcription bubble are poorly understood. For example, the non-template strand within the transcription bubble is more accessible than the template strand⁸¹ (Fig. 3A), but there is no deamination bias in favor of the non-template strand.^{68,69} An attractive model that overcomes this problem proposes that the RNA in the transcription bubble is removed by a ribonuclease exposing the template strand.^{82–84} However, it is unclear as to how the ribonuclease accesses 3' end of the nascent pre-mRNA for degradation. The RNA is paired with the template strand and lies deep within the RNA polymerase. Also, the forces that keep the two DNA strands apart after the degradation of RNA and removal of the polymerase from the DNA have not been described. Furthermore, if AID acts at transcription pause sites, it is not clear whether the pauses occur randomly along the DNA or are caused by specific events such as formation of secondary structure^{85,86} or the creation of DNA supercoiling domains.⁸⁷ Another possibility is that two convergent elongating polymerases could collide within the V(D)J segment causing transcription arrest and creating a region of single-strandedness (Fig. 2).⁸⁸ Interestingly, a single-molecule study showed that AID can cause T7 RNA polymerase elongation complexes to stall⁸⁹ eliminating the need for protein or structural factors to promote transcriptional pausing or stalling. This is similar to the original model for how AID may work^{73,74} and underlines the need for an *in*

vitro coupled transcription/deamination experimental model for answering many of the mechanistic questions about AID biochemistry.

Early work on AID did not provide direct experimental evidence that AID causes cytosine deaminations in the B cell genome. The role of AID in SHM was judged solely through genetics (loss of SHM in AID^{-/-} mice, ref.⁵⁰) or by determining mutation spectra in mice deficient in the repair of uracils (UNG^{-/-}, ref.⁹⁰) and/or base-base mismatches (MSH2^{-/-} or MSH6^{-/-}, references^{68,69,91}). More recent studies provide more direct evidence for the creation of uracils by AID.⁹²⁻⁹⁴

When DNA from splenocytes of immunized UNG^{-/-} mice was sequentially treated with *Escherichia coli* Ung and an AP endonuclease to generate strand breaks and the breaks were quantified, the breaks (and hence the uracils) were found to occur in both the V(D)J and the switch regions.⁹² This study showed that uracils were present in both the DNA strands of the switch region and estimated that there are about 0.8 uracils/10³ bp in the S_μ region of activated B cells.⁹² This number is several orders of magnitude higher than the number of uracils found in monocytes from un-immunized mice⁹⁵, but may not be sufficient to explain the double-strand breaks (DBSs) promoted by AID (see below). In a different study, uracils in DNA were replaced with biotin-containing tags, and total genomic uracils were quantified following *ex vivo* stimulation of WT and UNG^{-/-} splenocytes.⁹⁴

In UNG^{-/-} splenocytes, the genomic uracil levels increased about ten-fold in the first three days following stimulation, and this paralleled the increase in AID gene expression and nuclear DNA-cytosine deamination activity. The study estimated that the total number of uracils in the genome of UNG^{-/-} B cells was at least a few thousand⁹⁴, which is larger than what can be accounted for by the excess uracils in the Ig genes detected by the strand cleavage assay described above.⁹² This suggests that during the activation of B cells a large number of uracils are introduced in the genome, and most of the uracils lie outside the Ig genes.

When WT splenocytes were stimulated, UNG2 (the nuclear form of UNG) expression and nuclear uracil excision activity increased commensurate with the increase in AID expression and, in contrast to UNG^{-/-} splenocytes, no net increase in genomic uracils was detected. The lack of increase in uracil content was also seen in genomes of stimulated human tonsillar cells.⁹⁴ Hence, within the limits of detection of this assay, generation of genomic uracils and their removal are balanced during normal B cell maturation.

Although this study found that most uracils created by AID must lie outside Ig genes, it is unclear whether these uracils were in U:A or U•G pairs. The study used *E. coli* Ung to excise the uracils⁹⁴ and this enzyme excises uracils from both U•G and U:A pairs. Hence it is possible that some of the detected uracils resulted from the insertion of dU by DNA polymerases across from dA. Such incorporations of uracils in DNA have no mutagenic consequences. Mutations caused by AID in non-Ig genes are discussed below in the section 3.4.

3.2 Class-switch recombination

Following an infection, mammalian B cells undergo an additional genetic alteration, class-switch recombination (CSR, refs.^{96,97}). It is a region-specific recombination process that replaces constant heavy chain of immunoglobulins, μ , with one of the other chains (Fig. 2). This creates antibodies of different isotypes that interact with different cellular receptors to perform distinct immune functions. AID is essential for CSR.⁵⁰

AID promotes the formation of DSBs in the two switch regions⁹⁸ that participate in recombination that causes the isotype switch. The non-homologous end-joining or alternate end-joining processes connect the two broken ends replacing the μ constant segment with one of the downstream constant segments (Fig. 2, ref.⁹⁷). The critical unanswered question is how AID promotes the formation of DSBs. CSR is almost completely eliminated in UNG^{-/-} mice⁹⁰ and inactivation of MMR proteins MSH2 or MSH6 also reduces efficiency of CSR^{99,100} leading to the proposal that BER and MMR cooperate to generate the DSBs needed for CSR.^{96,97}

A possible way in which AID may promote the formation of DSBs is if the repair of U•G mispairs stops after hydrolysis of the AP sites by the AP endonuclease APE1. If this incomplete BER reaction pathway processed two closely spaced U•G mispairs with the uracils in opposite strands during a short time interval, a DSB would be created. Although, APE1 does appear to be required for CSR¹⁰¹, it is unclear how the subsequent steps in canonical BER are prevented from taking place. It is also unclear why this incomplete BER does not occur over the whole B cell genome. If incomplete BER were to happen on a genome-wide scale, potentially lethal strand breaks would be created during the repair of about 15,000 AP sites that occur in every cell per generation due to depurination.¹⁰² An additional problem with this pathway for generating DSBs is that the number of uracils in the S regions detected by Maul *et al*⁹² is not large enough to create closely spaced U•G mispairs. Therefore, the number of uracils generated by AID in the S regions is either underestimated or in the fraction of the cells undergoing CSR (which is generally <<50%) AID creates closely spaced uracils on opposite strands in a concerted fashion. Clearly, a great deal of additional work is needed to validate this pathway.

The dependence of efficient CSR on MMR may be explained by the binding of the MutS α (MSH2•MSH6) complex to other U•G mispairs in the S regions. One problem with this hypothesis is that the MMR is normally coordinated with DNA replication in the S phase to correct replication errors and AID is expressed mainly in the G1 phase. A possible answer to this problem may lie in a recently described non-canonical replication-independent mismatch repair (ncMMR) pathway in extracts of B cell tumor lines.^{103,104} In this process, binding of MutS α to U•G is followed by random nicking of DNA by the MutL α complex. Exonuclease 1 resects the DNA from these nicks and creates DSBs.¹⁰⁴ Regardless of the molecular details of how DSBs are created, it is unclear at this time whether U•G mispairs created by AID outside the Ig genes are also subject to ncMMR creating DSBs. Strand breaks outside the Ig genes have been detected during B cell stimulation¹⁰⁵ and it is possible that they are the result of incomplete BER or ncMMR of uracils created by AID outside Ig genes.

During CSR, mutations are also introduced in the two switch (S) regions in which DSBs are created (Fig. 2). The switch regions contain pentameric repeats with sequences such as GGGGT and GAGCT, and a majority of switch junctions lie at these repeats.¹⁰⁶ Deletions and base substitutions are frequently found near such junctions. The spectrum and distribution of substitution mutations in the switch regions are not as well-documented as V(D)J mutations, but they also have a preference for RGYW/WRCY targets¹⁰⁷, extend over several thousand base pairs and do not show a strand preference.¹⁰⁸ However, no biological function has been attributed to these mutations and they appear to be the result of a sloppy process of generating strand breaks. Consistent with this hypothesis, analysis of sequences of *Sμ* switch regions has shown that AID creates mutations in this region even without isotype switching.¹⁰⁷

3.3 DNA demethylation

The original suggestion that AID may play a role in DNA demethylation was based on the observation that 5-methylcytosines (5mC) in DNA is a substrate for AID. It was postulated that the T•G mispairs resulting from the deamination of 5mC could be repaired through base excision repair pathway restoring a C:G pair.^{109,110} Furthermore, detection of AID gene expression in oocytes and embryonic stem cells¹¹¹ was considered suggestive of AID's role in the erasure of DNA methylation during early stages of mammalian embryogenesis and stem cell development. However, AID was not found in testis^{111,112}, and genetic and biochemical studies of purified AID showed that 5mC is a poor substrate for AID.^{2,8,113–115} Subsequent discovery of the Tet enzymes which convert 5mC in DNA to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)^{116,117} and the detection of these modified bases in the genomes derived from both the parents within early embryos (reviewed in ref.¹¹⁸) makes it unlikely that AID plays a major role in genome-wide DNA demethylation that occurs during embryogenesis. Furthermore, the finding that the reactivity of AID towards C5-substituted cytosine decreases with increasing size of the substituent, makes it doubtful that AID plays a role in deaminating 5hmC, 5fC or 5caC in DNA.^{114,115,119} An analysis of the methylome in AID^{-/-} mice also did not support its role in DNA demethylation.¹²⁰ Despite these negative results, persistent reports suggest that AID may play a role in DNA methylation changes at a limited number of loci during cellular differentiation and establishment of pluripotency.^{121–125} Whether this role is enzymatic or structural remains unresolved at this time and availability of a mouse with catalytically inactive AID may help answer this question.

3.4 Genome-wide mutations and strand breaks

A number of studies have shown that AID targets cytosines outside the Ig genes causing mutations and strand breaks. Immunoprecipitation experiments showed that AID binds RNAP II¹²⁶ and ChIP analysis found that AID associates with nearly 6,000 genes in stimulated murine B cells.¹²⁷ The genes that recruited AID had a corresponding mRNA abundance that is 40 times greater than that of genes that do not recruit AID. In elongating genes, AID and RNAP II peak at the transcription start sites (TSS), and AID occupancy mirrors RNAP II density along the genes. A limited number of genes that recruit AID were sequenced and were found not be hypermutated in stimulated wild-type B cells. However, in

UNG^{-/-} background some non-Ig genes accumulated mutations at frequencies only ~10-fold lower than in the S_μ region.¹²⁷

In another study, when 1 kbp segments near 5' ends of over 80 genes expressed in germinal centers were sequenced from B cells undergoing maturation, 19% non-Ig genes were significantly mutated. The genes BCL6, CD83 and PIM1 had the highest level of AID-dependent mutations, while other genes including H2AFX had background mutation frequency.¹²⁸ MYC gene was modestly, but significantly, mutated.¹²⁸ However, the frequency of mutations in the Jh4 region in the VDJ segment was greater than 40 times the frequency in any other gene demonstrating that the VDJ segment is far and away the best target for hypermutations caused by AID in activated B cells. When the same genes were sequenced from cells of UNG^{-/-} MSH2^{-/-} mice, the percentage of genes with significantly higher mutations than background increased to 43%. However, in this background, BCL6, CD83 and PIM1 acquired mutations at only 1.6-fold the frequency found in WT cells. In contrast, mutation frequencies of several other genes were dramatically higher in the UNG^{-/-} MSH2^{-/-} cells. For example, frequency of mutations in the H2AFX and MYC genes respectively increased 18- and 14-fold.¹²⁸ Together these results show that AID deaminates cytosines in many non-Ig genes expressed in germinal center B cells, but high fidelity repair of the resulting uracils prevents mutations in most genes. However, uracils in several other genes are processed in the same error-prone manner as those in the V(D)J segment resulting in mutations (Fig. 2). The factors that determine whether or not U•G pair in a genomic region will be repaired through high fidelity repair need to be identified. It will also be useful to have results from a whole genome sequencing study of this kind to determine the genic and non-genic targets of AID and to delineate the features that make genomic regions susceptible to error-prone or high-fidelity repair.

As mentioned earlier, B cell stimulation results in the creation of strand breaks outside the Ig genes which are repaired through homologous recombination prior to DNA replication¹⁰⁵, but the location and numbers of these breaks have not been determined. In other studies, the locations of double-strand breaks generated by AID in the murine genome were determined by capturing them as translocations to engineered SceI endonuclease generated breaks.^{129,130} Although, a large fraction of AID-generated breaks were within the immunoglobulin loci, the remaining breaks were distributed throughout the murine chromosomes and correlated with actively transcribed genes. The frequency of AID-generated breaks peaked a few hundred bp downstream of TSS and correlated with hypermutated genes.^{129,130} These and other studies show that AID can target non-Ig genes and cause strand-breaks.^{84,88}

3.5 Cancer

While normal circulating B lymphocytes have undetectable levels of AID expression, most non-Hodgkins B cell lymphomas (B-NHLs) express AID at high levels^{131–135} These cells also show evidence of germinal center development such as SHM, CSR, or both. Additionally, their genomes contain translocations and non-Ig hypermutations. Typically, the translocations involve recombination between an Ig gene and a protooncogene such as MYC, BCL2 or BCL6.^{136,137} The biochemical steps leading from AID promoted DSBs to

chromosome translocations have been reviewed extensively^{138–140} and will not be discussed here.

In an IL6tg murine B cell plasmacytoma model, a critical step in cellular transformation was dependent on AID. When mice are treated with pristane, a chemical that causes chronic inflammation, or interleukin-6 (IL6), the animals acquire plasmacytomas and the tumors contain IgH-MYC translocations.^{141,142} However, these translocations were not found in IL6tg AID^{-/-} mice and the formation of lymphatic hyperplasia was delayed in these mice.¹⁴³ AID promotes the formation of these translocations by creating DSBs at both Myc and IgH loci.¹⁴⁴ AID was also required for germinal center-derived lymphomagenesis in a different lymphoma-prone mouse model.¹⁴⁵ These mice expressed BCL6, which is a master regulator of germinal center development and inhibits apoptosis. These and other results show that the principal role of AID in causing B cell non-Hodgkin's lymphomas is the ability of AID to generate DSBs near Myc, BCL6 and other oncogenes causing translocations that result in their dysregulation. In contrast, absence of AID had no impact on *Myc*-driven, pre-GC lymphomas¹⁴⁵, suggesting that only GC-derived B cell lymphomas depend on the expression of AID.

AID may play other roles in carcinogenesis in addition to promoting translocations. When bone marrow cells transduced with AID were transplanted into immune cell-depleted mice, the mice developed both B and T cell lymphomas.¹⁴⁶ The B cell lymphomas contained base substitution and addition/deletion mutations in genes EBF1 and PAX5 that are normally expressed in B cells, but did not contain *Myc-IgH* translocations. This suggests that the ability of AID to cause mutations may also play a role in tumor promotion.¹⁴⁶

Somewhat surprisingly, constitutive expression of AID in transgenic mice causes T cell lymphomas, but not B cell lymphomas.¹⁴⁷ These mice also develop lung microadenomas and adenocarcinomas and, less frequently, develop other types of tumors such as hepatocellular carcinomas, melanomas, and sarcomas.¹⁴⁸ In these mice, genes for T-cell receptor (TCR), MYC, PIM1, CD4, and CD5 were extensively mutated, but no large-scale clonal chromosome rearrangements such as IgH-c-myc translocations were found.^{147,149} These studies show that ectopic expression of AID can contribute to carcinogenesis, but is not sufficient for B cell cancers. As described above, a coordinated expression of other proteins such as BCL6 may be necessary to drive B cells to malignancy.

3.6 Inflammation and autoimmunity

Cytokine-mediated inflammatory responses are the first line of defense against viral infections. Examples of such cytokines include interferons α , β and γ (IFN- α , - β and - γ), interleukins and tumor necrosis factor α (TNF- α). These cytokines in turn activate several transcription factors such as NF- κ B and STAT¹⁵⁰ resulting in the expression of specific host proteins and activation of host defense mechanisms to clear the viral infection.¹⁵¹ These cytokines cause a wide range of changes in cellular function and body physiology that are collectively called inflammation.

AID expression is regulated by a number of proinflammatory cytokines. TGF- β , TNF- α and IL-1 β can stimulate AID expression via NF- κ B signaling in primary human hepatocytes and

reduce HBV infectivity in host cells.^{152–154} Moreover, AID expression is also enhanced by IL-4 and IL-13 in a STAT6 dependent manner in B cells and in human colonic epithelial cells.^{155,156} Thus AID expression is part of a broader inflammatory response following infection.

Chronic inflammation can be triggered by an autoimmune reaction and AID plays diverse and conflicting roles in regulating autoimmunity. Patients with AID deficiency fail to produce class-switched and affinity matured antibody isotypes and suffer from bacterial infection.¹⁵⁷ The role played by AID in preventing autoimmunity is illustrated by the observation that about 20 – 30% of these patients develop autoimmune diseases involving the production of non-hypermutated autoreactive unswitched (IgM) antibodies against self-tissues.¹⁵⁸ Examples of autoreactive antibodies in AID-deficient patients include an abnormal Ig repertoire encoding cold agglutinin antibodies that recognizes N-acetyllactosamine structures on red blood cells.¹⁵⁹ and an enrichment of clones with a long IgH CDR3¹⁵⁹, which favors self-reactivity.¹⁶⁰ In B cells that leave the bone marrow for further maturation, AID expression is necessary for the removal of autoreactive clones, perhaps by exerting genotoxic stress in conjunction with RAG2 and promoting apoptosis.^{161,162} Therefore, AID deficiency causes ineffective deletion of autoreactive B cells emerging from the bone marrow.

It is also possible that bacterial infection, a direct consequence of defective SHM and CSR in AID deficiency, leads to amplification of autoreactive B cells in the periphery.¹⁶³ Additionally, a reduction in peripheral blood regulatory T cells and an increase in circulating B cell-activating factor of the tumor necrosis factor family (BAFF)¹⁵⁹ may also aggravate B cell autoimmunity. Consistent with a role of AID in limiting autoimmunity in humans, AID^{-/-} mice have more severe autoimmune manifestations than their WT counterparts in certain specific genetic backgrounds.^{164,165}

Interestingly, while the deficiency of AID can precipitate B cell autoimmunity, uncontrolled AID expression can also promote B cell autoimmunity. In fact, AID-mediated germinal center reaction serves as an important source of autoantibodies.¹⁶⁶ Correlative studies found that B cells in the blood and ectopic synovial lymphoid follicles of rheumatoid arthritis patients have higher AID expression than those in osteoarthritis patients, and AID expression strongly correlates with serum rheumatoid factors.¹⁶⁷ The autoimmune-prone BXD2 mice harbor increased AID expression in splenic B cells as compared to B6 mice, with concomitant spontaneous formation of germinal centers and production of hypermutated autoreactive IgG.¹⁶⁸ Furthermore, AID-mediated SHM plays a critical role in the generation of high-avidity antinuclear antibodies in a mouse model of systemic lupus erythematosus (SLE).¹⁶⁹ AID^{-/-} and AID^{+/-} MRL/lpr mice show reduced or delayed lupus nephritis as compared to WT MRL/lpr mice.^{152,170}

These seemingly contradictory roles of AID in B cell autoimmunity may result from distinct stage-specific functions of AID during B cell differentiation. In the bone marrow, AID expression is required to purge autoreactive immature B cell clones by imposing genotoxic stress and promoting apoptosis. Whereas during the subsequent development of B cells in germinal centers and extrafollicular areas of secondary lymphoid organs, excessive AID-

mediated SHM can engender B cell autoreactivity. B cells also interact with other immune cells, such as T cells, and this interaction is also influenced by AID^{171,172}, further complicating the role played by AID in autoimmunity. These intricate immune regulatory circuits involving AID exemplify an emerging link between immunodeficiency and autoimmunity in many diseases.¹⁷³

4. APOBEC1

APOBEC1 can deaminate cytosines in both ssDNA and RNA. In humans APOBEC1 is expressed only in small intestine, and in rodents it is expressed in multiple tissues including the liver.¹⁷⁴

4.1 Lipid metabolism

The major physiological function of APOBEC1 is editing apolipoprotein B (apoB) mRNA and this affects lipid metabolism and transport. ApoB protein is found in two forms, ApoB-100 and ApoB-48. The larger ApoB-100 is synthesized in the liver and is the major protein component of LDL. The truncated form ApoB-48, is synthesized in the small intestine and is essential for chylomicron assembly and secretion. Unlike ApoB-100, ApoB-48 lacks the LDL receptor binding domain and as a result, ApoB-48 containing lipid vesicles are rapidly cleared from circulation.¹⁷⁵

A1 is the catalytic component of a complex that also contains auxiliary proteins including ACF (APOBEC1 complementation factor) and ASP (APOBEC1 stimulating protein).^{176,177} A1 deaminates cytosine in the codon 2153 (C⁶⁶⁶AA) in ApoB mRNA to uracil creating an in-frame stop codon.^{7,178} This causes a premature translation termination and creation of the shorter apoB-48 protein.

Recent studies show in addition to *apoB* mRNA APOBEC1 can deaminate cytosines in several other RNAs.^{179,180}

Apart from editing cytosines in RNA, A1 also has the ability to deaminate cytosines in DNA.⁴⁸ The target sequence context is different for RNA and DNA. Whereas the target cytosine in ApoB mRNA is flanked by an adenine on the 5' side, *E. coli* genetic assays and biochemical assays with purified protein suggest that in DNA the preferred 5' nucleotide is a pyrimidine.^{5,48} The physiological function of DNA editing by A1 has not been established.

4.2 Cancer

An early investigation of transgenic mice and rabbits expressing A1 found that the animals showed liver abnormalities and developed hepatocellular carcinoma.¹⁸¹ Mice expressing a truncated form of A1 did not show these abnormalities. In addition to the editing of apoB mRNA, other mRNAs in the liver were found to be edited in transgenic mice.¹⁸¹ At the time of these studies APOBEC1 was known to act only on RNA and hence the malignant transformation was attributed to aberrant editing of mRNA for a protein with homology with a translation factor.^{179,181} There is a need to revisit this issue by determining genomic uracils, mutations and genomic rearrangements in hepatic carcinoma created by the dysregulation of A1.

5. APOBEC3 subfamily

There is currently no authentic animal model for the studies of individual APOBEC3 genes and proteins because rodents have a single APOBEC3 gene, while humans have seven APOBEC3 genes.¹⁸² Consequently, most experiments with human APOBEC3s are done using primary or immortalized cells of human or non-human origin, and the results are often dependent on the specific cell line being used. This has created significant confusion regarding the expression of some the APOBEC3 proteins and their biological function.

5.1 Cytokines and expression of APOBEC3 genes

Several APOBEC3 genes are up-regulated in response to cytokine treatment of cells. While some APOBEC3 genes are expressed constitutively in some tissues, expression of other APOBEC3s is cytokine responsive.^{183,184}

The genes for A3A, A3F and A3G, but not A3B or A3C, are upregulated by IFN- α in several hematopoietic cells including dendritic cells, macrophages and naïve CD4⁺ T cells.^{184,185} IFN- α enhances A3G expression in cells that are targets of HIV-1 infection, resting CD4⁺ T cells¹⁸⁶, human peripheral plasmacytoid dendritic cells¹⁸⁷ and macrophages.^{185,188} Moreover, INF- α and IFN- γ enhance the expression of A3F and A3G in primary human brain microvascular endothelial cells, the major component of blood-brain barrier, presumably to restrict HIV-1 entry into the central nervous system.¹⁸⁹ A3G is also induced by several other factors including IL-2, IL-15, and to a lesser extent IL-7, in peripheral blood lymphocytes and by TNF- α during the maturation of dendritic cells which are different cellular targets of HIV.¹⁸⁸

Hepatitis B virus (HBV) infection of hepatocytes results in expression of cytokines and various APOBEC3 proteins. A3G gene has an IFN response element and its expression is upregulated upon stimulation of cells with IFN- α .¹⁹⁰ In primary human hepatocytes or HBV infected liver cells A3A, A3B, A3F and A3G expression is induced by IFN- α .^{191,192} Additionally, treatment of a cervical keratinocyte cell line that contains episomal HPV16 genomes with IFN- β results in increased expression of A3A, A3F and A3G genes.¹⁹³ The studies described above collectively show that expression of APOBEC3 genes is an important part of cytokine-mediated inflammatory response.

5.2 Clearance of foreign DNA

There are several mechanisms in mammals to detect and eliminate foreign DNA circulating in bodily fluids. Dendritic cells and macrophages detect foreign DNA unmethylated at CpG sequences through toll-like receptor 9 in endosomal compartments.¹⁹⁴ Additional DNA sensors include the complex “stimulator of interferon genes” (STING), “DNA-dependent activator of IFN regulatory factor” (DAI), “absent in melanoma-2” (AIM2) and RNA polymerase III.^{195–197} Together they participate in signaling pathways that produce pro-inflammatory cytokines and chemokines such as TNF α and type I interferons resulting in the transcription of effector genes to elicit a broad innate immune response.^{196,198–200} The subsequent steps in the process of clearance of foreign DNA are less characterized, but APOBEC3 proteins may play a role in it.

Expression of A3A increases more than 100-fold in response to interferon treatment of cells such as monocytes and macrophages, which ingest foreign objects like bacteria and viruses.^{183,201} A3A expression affects the integrity and stability of foreign DNA reducing gene transfer efficiency, inhibiting transient gene expression and destabilizing foreign plasmid DNA. Differential DNA denaturation PCR (3DPCR) and an UNG inhibitor were used to demonstrate that the foreign DNA underwent deamination of cytosines to uracils.²⁰¹ A subsequent study showed that A3A expressed in monocytes was predominantly cytoplasmic and its optimal activity occurred in acidic pH range found in endosomes.^{202,203} Methylation of CpGs suppresses cellular recognition of foreign DNA²⁰⁴ and among the AID/APOBEC family members, A3A is most efficient at deaminating 5mC.^{8,205,206} This raises the interesting possibility that the ability of A3A to deaminate 5mCs in DNA is related to clearance of viruses that carry CpG methylation.²⁰⁷ Family members such as A3G would be ineffective at this task because of their inability to deaminate 5mC.⁸

5.3 Immunity against RNA viruses

APOBEC3 subfamily proteins contribute to innate immunity by restricting viral infection and propagation.^{51,208} The first APOBEC3 protein shown to have activity that restricts HIV infection was A3G.²⁰⁹ Restriction of HIV by APOBEC3s has been reviewed extensively^{210–212} and will not be described here in detail. Briefly, early work showed that A3G protein is incorporated into HIV-1 particles and during reverse transcription of the viral RNA, A3G deaminates cytosines in minus-strand DNA to cause G to A mutations^{213,214} and creates non-infectious virions. Additionally, it has been suggested that excision of uracils created by APOBECs by the cellular uracil-DNA glycosylase may result in the degradation of viral DNA²¹⁵ However, the reverse transcription of viral RNA takes place in the cytoplasm and only mitochondrial (UNG1) and nuclear (UNG2) forms of UNG have been described previously²¹⁶ Thus the interaction between the UNG protein and the DNA copy of the viral genome needs to be studied in greater detail.

HIV encodes the protein virion-infectivity factor (Vif) that abrogates restriction of HIV by A3G and other APOBEC3 family members²¹⁵ and thus the above-mentioned experiments were done using Vif⁻ strains of HIV. Vif prevents A3G incorporation into the progeny virus and directs its degradation by a proteasome-dependent pathway.^{217–219} The interactions of Vif with CUL5-RBX2, ELOB-ELOC and CBF β to form ubiquitin ligase E3 and its interactions with APOBEC3 family proteins has been described in detail^{210,220–223} and will not be described further.

A3D/E, A3F and A3H haplotypes II, V and VII, may also provide protection against Vif-deficient HIV-1 in tissue culture models.²²⁴ Using humanized mouse models it was also shown that several APOBEC3 enzymes (A3G, A3D, A3F) can restrict HIV-1 *in vivo*²²⁵ Some studies also report that A3A, A3B and A3C are capable of inhibiting HIV infection^{210,226,227}, but their significance is controversial.^{228,229} This is partly because some members, including A3B, are able to inhibit wild type Vif-proficient HIV, but are not normally expressed in T cells that are the primary targets of HIV infection.²²⁷

Subsequently, HIV-1 restriction was also observed with catalytically defective variants of A3G and A3F, hence a deaminase independent mechanism may also inhibit HIV growth.

The prevailing model to explain this phenomenon invokes binding of APOBEC protein to viral RNA and blocking the reverse transcription of viral genome.²¹¹ In summary, in CD4⁺ T cells both editing and non-editing mechanisms mostly by A3G, and to lesser extent by A3F and A3D/E, contribute to the restriction of Vif-defective HIV-1.²³⁰

In addition to HIV, APOBEC proteins have been reported to restrict or mutate a broad range of RNA viruses including other retroviruses such as human T-cell leukemia virus type-1 (HTLV-1)^{231–233} and human foamy virus.²³⁴ A3G appears to play a major role in restricting both HTLV-1²³² and foamy viruses.²³⁴ Also, other reports suggest that, like HIV, these viruses may also express proteins that counteract the APOBEC3G protein^{235–238} and hence this issue needs further examination.

5.4 Immunity against DNA viruses

DNA viruses including adeno-associated virus (AAV), hepatitis B virus (HBV), human papillomavirus (HPV) and herpes viruses such as herpes simplex-1 (HSV-1) and Epstein-Barr Virus (EBV) have been reported to be restricted by APOBEC3s.^{51,208,239}

AAV is a nuclear replicating parvovirus that is restricted by A3A, but not A3G.^{240,241} 3DPCR was used to show that the genome of another nuclear replicating virus, HBV, mutated at different levels by a number of APOBECs including A3A, A3B, A3C, A3F and A3G.^{242,243} Cytokine-mediated upregulation of A3A and A3B results in the degradation of HBV covalently closed circular nuclear DNA without apparent damage to the host genomic DNA.¹⁹²

HPV is a double stranded DNA virus that infects skin cells and infection of keratinocyte cell line with HPV E6 results in expression of A3B.²⁴⁴ Again, 3DPCR was used to show that HPV was hyperedited when A3A, A3B and A3H enzymes were transiently overexpressed.²⁴⁵ In another study hypermutation of HPV16 in cervical keratinocytes were seen when A3A, A3F and A3G were upregulated following IFN- β treatment.¹⁹³ Both HSV-1 and EBV genomes may be susceptible to editing by A3C expressed in HeLa cells and overexpression of A3C through transfection results in the reduction of both viral titers and infectivity by HSV-1.²⁴⁶ Edited EBV DNA was also found in infected peripheral blood mononuclear cell lines in association with high levels of A3C expression.²⁴⁶

Although these studies collectively suggest that APOBEC3 proteins mutate many human viruses, there are several concerns about these data. It is unclear how A3G, which is found almost exclusively in the cytoplasm, can edit nuclear replicating EBV and HSV-1 viruses.^{242,246} There are also hints that, like HIV, other human viruses may employ protective measures against APOBEC3 proteins and there is a need to investigate them further. For example, most herpes viruses code their own UNG (vUNG) proteins that are expressed at the onset of DNA replication. Furthermore, it has been shown that inactivation of vUNG in several herpes viruses reduces viral replication.^{247–249} It would be interesting to investigate whether vUNG proteins provide protection against the action of AID/APOBEC family enzymes on herpes viral genomes.

Another significant concern is that a good deal of the work regarding antiviral effects of APOBEC3s is based on analysis of mutations in viral genomes using the technique of 3DPCR.²⁵⁰ It uses lower than normal temperatures during the denaturation step in PCR and thus selectively amplifies a fraction of molecules within the products that contain multiple mutations. This has the potential of exaggerating the mutational effects of APOBEC3s. It has also been shown that this procedure introduces mutations in PCR products at a frequency of 1 in 500 bp²⁵¹, which is at least an order of magnitude higher than normal PCR. It would be useful to use high fidelity PCR and deep sequencing technologies to reexamine mutational effects of APOBEC3s in human viruses.

5.5 Inhibition of retrotransposition

There are two major classes of retroelements in mammalian cells. One class includes elements with long terminal repeats (LTRs) such as endogenous retroviruses and the second class consists of non-LTR retroelements such as the long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs). APOBEC proteins inhibit retrotransposition of both kinds of retroelements.

A3A, A3B, A3C and A3F have a strong inhibitory effect on non-LTR retroelements, specifically LINE-1 (L1) and Alu elements.^{252–254} A3B and A3F are thought to inhibit L1 transposition through a deamination-dependent mechanism.²⁵⁵ Although the involvement of A3G against non-LTR retroelements is controversial^{256,257}, A3G can suppress the retrotransposition of mouse LTR retrotransposons MusD and IAP as well as yeast Ty1 retrotransposon.^{258,259} Similarly A3A, A3B, A3C and A3F have been shown to inhibit these LTR retrotransposition.²⁵⁶

Almost half the human genome consists of DNA transposons and retroelements²⁶⁰ and mutational footprints of APOBEC3s can be found in many such sequences.²⁶¹ There is considerable evidence that the spread of these elements has occurred sporadically in the evolution of eukaryotes including primates.^{262–264} It is possible that the expansion of APOBEC3s from one or two genes in the common ancestor of mammals to seven genes in primates¹⁰ may be explained by bursts of retrotransposition activity over 100 million years of mammalian evolution.

5.6 Genome-wide mutations and cancer

The potential of AID for causing mutations in the cellular chromosomes was recognized even before the enzyme was discovered^{265,266}, but similar hazard was not associated with the other enzymes in the family for over a decade following their discovery. This slothful scientific slumber was rudely disturbed by the publication by Nik-Zainal *et al* describing several breast cancer tumors with APOBEC3 mutational signatures.^{267,268} These whole genome sequencing (WGS) studies identified APOBEC3-specific mutational signature, C to T or C to G mutations in TCW sequence context, in the tumor genomes and found that the mutations are often clustered.²⁶⁸ Additionally, the TCW sequences in these mutational clusters tend to have the target cytosines in the same DNA strand, a phenomenon referred to as strand-coordinated mutations.^{268–270} Subsequently, this signature was also found in more than a dozen different types of cancers including those of head-and-neck and

cervix.^{267,269,271,272} Additionally, expression of A3B was correlated with occurrence of breast²⁷³ and other cancers^{274,275}, and other studies have implicated both A3A and A3B in cancer genome mutations.²⁷⁶ It should be noted that all the APOBEC3s with the exception of A3G have essentially the same mutational signature, and hence these mutations are collectively referred to as APOBEC signature mutations. It is now clear that some members of the APOBEC3 family play a significant role in causing mutations in cancer genomes²⁷⁷, but whether they play a role in driving carcinogenesis and tumor progression remains unclear.

One analysis of both breast and lung tumor sequences found that mutations with APOBEC signature were more prevalent in early replicating regions and that this was opposite of the distribution of most other somatic mutations in these cancers which were found in late replicating regions.²⁷⁸ Furthermore, these mutations were not correlated with transcription suggesting that they were unlikely to have the same underlying mechanism as AID-generated genomic mutations. In a different study, A3A was expressed from a regulated *Tet* promoter and expressed either in cells blocked in the G1 phase or released from G1 and allowed to enter the S phase. The latter cells acquired more genomic uracils and strand breaks than the cells in G1.²⁷⁹ Together, these studies implicate replication forks as targets for APOBEC3s.²⁸⁰

This correlation between replication and APOBEC-generated cytosine deaminations was confirmed and extended through further analysis of strand-coordinated mutations in cancer genomes with APOBEC signature.^{281,282} In both the studies, the origins of replication (ORI) were assumed to lie at the intersection of replication timing versus distance plots for the left- and right-replicating forks. Based on this identification of ORI, APOBEC signature mutations were assigned to the two replication strands, the lagging strand template (LGST) and the leading strand template (LDST). This analysis found that 50% to 100% more mutations were in the LGST compared to the LDST.^{281,282} This preferential targeting of LGST by APOBEC3s may be explained by the fact that the LGST spends more time in a single-stranded state than the LDST.²⁸³

Studies using yeast²⁸⁴ and *E. coli*²⁸⁵ genetic systems have provided strong experimental evidence in support of this hypothesis. When A3G-CTD was expressed in an *ung⁻* mutant *E. coli* and the resulting mutations were determined by WGS in 50 independent cell lines grown for over 1,000 generations, the resulting C:G to T:A mutations had a strong strand bias. There were 3- to 4-times as many transition mutations with the cytosine in LGST than in LDST.²⁸⁵ The bulk of the C:G to T:A mutations were in runs of C's indicating that they were likely to have been caused by A3G-CTD and the strand bias was greatly diminished when a catalytically defective mutant was expressed in the cells.²⁸⁵

When the catalytic domain of A3G (A3G-CTD) was expressed in an engineered *ung1* yeast strain, the mutation frequency in a reporter gene in the ssDNA region generated through aberrant resection of telomeric ends increased substantially.²⁸⁶ This showed that A3G can target ssDNA in the yeast genome. In a different study, expression of A3A or A3B in an *ung1*-defective, but otherwise normal, yeast strain produced strand-coordinated mutations linked to replication.²⁸⁴ The mutations were predominantly G:C to A:T when the

reporter gene was on the 5' side of ORI, but C:G to T:A mutations dominated when the same reporter was on the 3' side of the ORI. Furthermore, destabilization of replication through the use of a yeast mutants defective in RPA, the single-strand DNA-binding protein, or Tof1, a protein that couples replicative polymerases with the helicase that opens the replication fork, increased the frequency of mutations caused by A3A and A3B.²⁸⁴ A large increase in mutation frequency was also seen when the cells were treated with hydroxyurea, a chemical known to cause replication stress. Unexpectedly, the strand bias in mutations disappeared on the 5' side, but not the 3' side, of the ORI in both the Tof1 mutant strain and in cells treated with hydroxyurea.²⁸⁴ Finally, the strand-coordinated mutations caused by A3A and A3B were more often clustered when the replication fork was disturbed compared to untreated wild-type cells and are reminiscent of the clustered mutations seen in cancer genomes²⁶⁸

The following model (Fig. 3B) can explain mutations and strand breaks observed in dividing cells expressing APOBECs. Most cytosines in the LDST will be inaccessible to APOBECs because they will be in double-stranded DNA. Cytosines in the single-stranded gaps between Okazaki fragments will be deaminated by the APOBECs and most of these uracils will be copied immediately by the replicative DNA polymerase δ creating C:G to T:A mutations. Occasionally, UNG2 may excise the uracil before a polymerase has a chance to copy it, and the resulting AP site may be copied by TLS polymerase η again creating the same mutation in most cases.⁶⁵ Alternately, the abasic site may be copied by REV1 creating C:G to G:C transversions.^{66,67} Finally, if AP endonuclease APE1 acts on the AP site before TLS bypass of the AP site, a double strand break will occur (Fig. 3B). These may be the strand breaks observed by Green *et al*²⁷⁹ when they expressed A3A in the S phase. Thus expression of APOBECs during replication should cause genome instability in addition to generating mutations.

In contrast to these results in dividing cells, Lada *et al* found that genome-wide mutations caused by the lamprey DNA-cytosine deaminase, PmCDA1, in non-dividing yeast were often clustered and the occurrence of clusters was correlated with known transcription levels of the target genes.^{287,288} Furthermore, more mutations were in the 5'-UTRs than in the bodies of the genes, and there were substantially more C to T mutations in the non-transcribed DNA strand than in the transcribed strand in all the parts of the genes.²⁸⁷ This result is well-explained by the observation that the non-transcribed strand is more susceptible to damage than the transcribed strand^{75,289} (Fig. 3A). Together, these observations suggest that in dividing cells, the APOBEC enzymes preferentially target cytosines in the LGST, but in non-dividing cells the preference may shift to cytosines in the non-transcribed strand of actively transcribed genes.

5.7 Linking virus infection, APOBEC3 expression and cancer

As mentioned above, there is currently no animal model for studying the role of APOBEC3 proteins in carcinogenesis. However, a number of lines of evidence suggest that these proteins play an important role in promoting malignant transformation.

About 15–20% of human cancers are attributed to viruses²⁹⁰ and these tumor viruses are distributed throughout DNA and RNA virus families.²⁹¹ They include DNA viruses such as

HPV, EBV and human herpes virus 8/ Kaposi's sarcoma-associated herpes virus, and RNA viruses including human T-lymphotrophic virus-1 and HCV.²⁹² However, virus infected cells launch an innate immune response, in part, by releasing cytokines such as interferons and interleukins.²⁹³ In general, the release of these cytokines has been linked to cancer through the generation of oxidative stress, stimulation of pro-growth signal transduction pathways, and synthesis of chemokines and growth factors.^{293,294} While it is possible that these molecules and pathways play major roles in causing DNA damage and promoting cancer, AID/APOBEC proteins may also play a role in this transformation.

As discussed in section 5.1, cytokines produced during viral infections trigger the expression of AID/APOBEC proteins and as discussed in sections 3.4 and 5.6 these enzymes can cause genome-wide mutations. Therefore, AID/APOBEC expression could be a key link between viral infection and malignant transformation (Fig. 4). What remains unclear at this point is whether or not APOBEC enzymes cause a significant fraction of the driver mutations or genome rearrangements seen in cancers. Consequently, there is an urgent need for the development of new animal models to study the link between APOBEC enzymes and cancer.

5.8. Functional convergence of AID and APOBEC enzymes

The AID/APOBEC field was trifurcated at its birth. RNA and lipid biochemists who study RNA editing by APOBEC1 and its role in lipid metabolism reside on the first leaf of this three-leaf clover. One report showed 20 years ago that A1 may cause liver cancer, but there have been no further reports confirming or refuting this observation. There have also been few studies of the effects of A1 expression on cellular genome mutations. Virologists have resided on the second leaf of this Shamrock studying the role of APOBEC3 subfamily in innate immunity and inhibition of virus growth. Although APOBEC3 family members were shown to bind RNA and this binding has a role in antiviral function of the proteins, no evidence was presented that they may act as RNA-cytosine deaminases. The possible role of APOBEC3 enzymes in causing genomic mutations and promoting cancer was also rarely examined. On the last leaf of this Shamrock lie immunologists and tumor biologists who are focused on the role of AID in antibody maturation and B cell cancers. The studies of the role of AID in carcinogenesis have focused on DSBs and translocations with only a few studies exploring the non-Ig gene mutations. Despite an early observation that AID binds RNA², the functional significance of this observation was not explained.

Luckily, a number of recent studies suggest that this separate progress in the three separate fields is about to converge, especially when it comes to AID and APOBEC3 enzymes. Recently, A3A was implicated in C to U editing in RNA⁹ and, more surprisingly, in G to A editing in RNA.²⁹⁵ Additionally, AID was shown to bind intronic RNA from the switch regions and the evidence suggests that this bound RNA guides the enzyme to the switch regions and is essential for CSR.²⁹⁶ It is likely that all members of the AID/APOBEC family bind RNA and this binding is biologically relevant. The implicit assumption that APOBEC3 enzymes act only on viral or retrotransposition intermediates must be set aside in view of the work of Nik-Zainal *et al*²⁶⁸ and others. Interestingly, the APOBECs were shown to act at replication forks^{281,282,284,285} creating a contrast with AID which was known to act only on

actively transcribed genes. However, Le and Maizels²⁹⁷ recently showed that this dichotomy is not dictated by the biochemistry of AID, but is probably the result of a lack of expression of AID in the S phase. If AID is expressed in the S phase it causes strand breaks in the same way as A3A.^{279,297} Lastly the link between the expression of AID and APOBEC3s with inflammation suggests that they may share more unexplored biology than previously suspected.

6. Concluding Remarks

The AID/APOBEC family is unique among all known enzymes in that most members of this family cause damage to a DNA base and the biological purpose of this action is to cause base substitution mutations and strand breaks. Vertebrates express these enzymes to gain immunity against infections and *Homo sapiens* appear to have the highest number of genes for these enzymes. However, this protective strategy requires that these enzymes perform a high-wire act in which they mutate the foreign genomes (or the host immunoglobulin genes) without damaging much of their own genome. This is the genetic equivalent of playing with fire and it is increasingly becoming clear that it fails in some cells and get badly burnt. In particular, many members of the AID/APOBEC family are implicated as the source of mutations found in many cancers and some of these mutations may drive carcinogenesis. We need to learn a great deal more about the regulation of these enzymes in response to infections, the role of different family members in restricting different human viruses under biologically relevant conditions, the kind and amount of damage they cause to the host genome, the cellular mutation avoidance mechanisms that limit such damage, and the contributions of the DNA damage that escapes repair to cellular dysfunction including their malignant transformation.

Acknowledgments

Molecular graphics were generated using the UCSF Chimera package. We would like to thank Ms. Shanjiao Wei and Jessica Stewart (Wayne State University) for help with a figure and Dr. Thomas Holland (Wayne State University) for comments on the manuscript. The research in the Bhagwat laboratory was supported by national Institutes of Health grant GM 57200 and funds from the Wayne State University office of Vice-President for research. Research in the Chen laboratory was supported by grants from the National Institutes of Health (U01AI95776 Young Investigator Award, R21AI122256 and Grant P30CA22453), the Burroughs Wellcome Fund, American Congress of Obstetricians and Gynecologists and Wayne State University Maternal, Perinatal and Child Health Initiative.

Biographies

Sachini U. Siriwardena was born in Colombo, Sri Lanka in 1987. She earned a B.Sc. in Molecular Biology and Biochemistry with first class honors in 2011 from the University of Colombo. Subsequently, she worked as a temporary Assistant Lecturer in the same institute for one year. Currently she is pursuing a Ph.D. degree in Biochemistry at the Wayne State University under the guidance of Ashok Bhagwat.

Kang Chen is an Assistant Professor at Wayne State University since 2012. He studied at the National University of Singapore on a Singapore government scholarship and graduated with First-Class Honors in Biochemistry. He received Ph.D. in Immunology and Microbial Pathogenesis from Weill Cornell Medical College and Memorial Sloan-Kettering Cancer

Center and did postdoctoral research at Icahn School of Medicine at Mount Sinai. He also worked with the United Nations Human Settlements Programme (UN-HABITAT) on initiatives of sustainable urbanization and public health. He has published articles in Science, Nature Immunology, Immunity, Annual Review of Immunology, Journal of Clinical Investigation, received many prestigious awards, such as Singapore Lijen Industrial Development Medal, Charles Janeway Memorial Award, Vincent du Vigneaud Award of Excellence, and is a Burroughs Wellcome Fund investigator in preterm birth. Research in his lab is focused on the regulation of antibody diversification, mucosal immunology and immune pathogenesis of reproductive disorders.

Ashok S. Bhagwat is a Professor of Chemistry, and Immunology and Microbiology at Wayne State University. He obtained B.Sc. and M.Sc. in Physics from the University of Bombay and the Indian Institute of Technology, Bombay, respectively. His interest in biological research was stimulated at the Indian Institute of Science, Bangalore and he eventually obtained a Ph.D. in Biophysics from Pennsylvania State University. Following post-doctoral work at Cold Spring Harbor laboratory, he joined Wayne in 1988. His research interests include the biochemistry of DNA-acting enzymes and is a hopeless romantic about the importance of basic research in science.

References

1. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. *Journal of molecular biology*. 2004; 337:585. [PubMed: 15019779]
2. Bransteitter R, Pham P, Scharff MD, Goodman MF. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. *Proceedings of the National Academy of Sciences of the United States of America*. 2003; 100:4102. [PubMed: 12651944]
3. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. *Nature*. 2003; 422:726. [PubMed: 12692563]
4. Dickerson SK, Market E, Besmer E, Papavasiliou FN. AID mediates hypermutation by deaminating single stranded DNA. *The Journal of experimental medicine*. 2003; 197:1291. [PubMed: 12756266]
5. Petersen-Mahrt SK, Neuberger MS. In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1). *The Journal of biological chemistry*. 2003; 278:19583. [PubMed: 12697753]
6. Sohail A, Klapacz J, Samaranayake M, Ullah A, Bhagwat AS. Human activation-induced cytidine deaminase causes transcription-dependent, strand-biased C to U deaminations. *Nucleic Acids Res*. 2003; 31:2990. [PubMed: 12799424]
7. Teng B, Burant CF, Davidson NO. Molecular cloning of an apolipoprotein B messenger RNA editing protein. *Science (New York, NY)*. 1993; 260:1816.
8. Wijesinghe P, Bhagwat AS. Efficient deamination of 5-methylcytosines in DNA by human APOBEC3A, but not by AID or APOBEC3G. *Nucleic Acids Res*. 2012; 40:9206. [PubMed: 22798497]
9. Sharma S, Patnaik SK, Taggart RT, Kannisto ED, Enriquez SM, Gollnick P, Baysal BE. APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages. *Nature communications*. 2015; 6:6881.
10. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jonsson SR, Landau NR, Lochelt M, et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. *Journal of virology*. 2009; 83:494. [PubMed: 18987154]

11. Conticello SG. The AID/APOBEC family of nucleic acid mutators. *Genome biology*. 2008; 9:229.
12. Neuberger MS, Harris RS, Di Noia J, Petersen-Mahrt SK. Immunity through DNA deamination. *Trends in biochemical sciences*. 2003; 28:305. [PubMed: 12826402]
13. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. *Genomics*. 2002; 79:285. [PubMed: 11863358]
14. Pham P, Bransteitter R, Petruska J, Goodman MF. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. *Nature*. 2003; 424:103. [PubMed: 12819663]
15. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. *Nat Rev Immunol*. 2004; 4:868. [PubMed: 15516966]
16. Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS. The APOBEC-2 crystal structure and functional implications for the deaminase AID. *Nature*. 2007; 445:447. [PubMed: 17187054]
17. Byeon IJ, Ahn J, Mitra M, Byeon CH, Hercik K, Hritz J, Charlton LM, Levin JG, Gronenborn AM. NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. *Nature communications*. 2013; 4:1890.
18. Bohn MF, Shandilya SM, Silvas TV, Nalivaika EA, Kouno T, Kelch BA, Ryder SP, Kurt-Yilmaz N, Somasundaran M, Schiffer CA. The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization. *Structure (London, England: 1993)*. 2015; 23:903.
19. Kitamura S, Ode H, Nakashima M, Imahashi M, Naganawa Y, Kurosawa T, Yokomaku Y, Yamane T, Watanabe N, Suzuki A, et al. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. *Nature structural & molecular biology*. 2012; 19:1005.
20. Shi K, Carpenter MA, Kurahashi K, Harris RS, Aihara H. Crystal Structure of the DNA Deaminase APOBEC3B Catalytic Domain. *The Journal of biological chemistry*. 2015; 290:28120. [PubMed: 26416889]
21. Bohn MF, Shandilya SM, Albin JS, Kouno T, Anderson BD, McDougale RM, Carpenter MA, Rathore A, Evans L, Davis AN, et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. *Structure (London, England: 1993)*. 2013; 21:1042.
22. Siu KK, Sultana A, Azimi FC, Lee JE. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. *Nature communications*. 2013; 4:2593.
23. Harjes E, Gross PJ, Chen KM, Lu Y, Shindo K, Nowarski R, Gross JD, Kotler M, Harris RS, Matsuo H. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. *Journal of molecular biology*. 2009; 389:819. [PubMed: 19389408]
24. Holden LG, Prochnow C, Chang YP, Bransteitter R, Chelico L, Sen U, Stevens RC, Goodman MF, Chen XS. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. *Nature*. 2008; 456:121. [PubMed: 18849968]
25. Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, Hayashi F, Kobayashi N, Yokoyama S, Takaku H, Katahira M. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. *The EMBO journal*. 2009; 28:440. [PubMed: 19153609]
26. Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res*. 2014; 42:W320. [PubMed: 24753421]
27. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera—a visualization system for exploratory research and analysis. *Journal of computational chemistry*. 2004; 25:1605. [PubMed: 15264254]
28. Carpenter MA, Rajagurubandara E, Wijesinghe P, Bhagwat AS. Determinants of sequence-specificity within human AID and APOBEC3G. *DNA repair*. 2010; 9:579. [PubMed: 20338830]
29. Kohli RM, Abrams SR, Gajula KS, Maul RW, Gearhart PJ, Stivers JT. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. *The Journal of biological chemistry*. 2009; 284:22898. [PubMed: 19561087]
30. Wang M, Rada C, Neuberger MS. Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID. *The Journal of experimental medicine*. 2010; 207:141. [PubMed: 20048284]

31. Bulliard Y, Narvaiza I, Bertero A, Peddi S, Rohrig UF, Ortiz M, Zoete V, Castro-Diaz N, Turelli P, Telenti A, et al. Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. *Journal of virology*. 2011; 85:1765. [PubMed: 21123384]
32. Gajula KS, Huwe PJ, Mo CY, Crawford DJ, Stivers JT, Radhakrishnan R, Kohli RM. High-throughput mutagenesis reveals functional determinants for DNA targeting by activation-induced deaminase. *Nucleic Acids Res*. 2014; 42:9964. [PubMed: 25064858]
33. Rathore A, Carpenter MA, Demir O, Ikeda T, Li M, Shaban NM, Law EK, Anokhin D, Brown WL, Amaro RE, et al. The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution. *Journal of molecular biology*. 2013; 425:4442. [PubMed: 23938202]
34. Chen Q, Xiao X, Wolfe A, Chen XS. The in vitro Biochemical Characterization of an HIV-1 Restriction Factor A3F: Importance of loop 7 on both CD1 and CD2 for DNA binding and deamination. *Journal of molecular biology*. 2016; doi: 10.1016/j.jmb.2016.03.031
35. Bransteitter R, Pham P, Calabrese P, Goodman MF. Biochemical analysis of hypermutational targeting by wild type and mutant activation-induced cytidine deaminase. *The Journal of biological chemistry*. 2004; 279:51612. [PubMed: 15371439]
36. Logue EC, Bloch N, Dhuey E, Zhang R, Cao P, Herate C, Chauveau L, Hubbard SR, Landau NR. A DNA sequence recognition loop on APOBEC3A controls substrate specificity. *PloS one*. 2014; 9:e97062. [PubMed: 24827831]
37. Brar SS, Sacho EJ, Tessmer I, Croteau DL, Erie DA, Diaz M. Activation-induced deaminase, AID, is catalytically active as a monomer on single-stranded DNA. *DNA repair*. 2008; 7:77. [PubMed: 17889624]
38. Chelico L, Sacho EJ, Erie DA, Goodman MF. A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. *The Journal of biological chemistry*. 2008; 283:13780. [PubMed: 18362149]
39. Shlyakhtenko LS, Lushnikov AJ, Li M, Harris RS, Lyubchenko YL. Interaction of APOBEC3A with DNA assessed by atomic force microscopy. *PloS one*. 2014; 9:e99354. [PubMed: 24905100]
40. Shlyakhtenko LS, Lushnikov AY, Li M, Lackey L, Harris RS, Lyubchenko YL. Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. *The Journal of biological chemistry*. 2011; 286:3387. [PubMed: 21123176]
41. Chiu YL. Biochemical fractionation and purification of high-molecular-mass APOBEC3G complexes. *Methods in molecular biology* (Clifton, NJ). 2011; 718:185.
42. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Opi S, Takeuchi H, Strebel K. HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. *Virology*. 2008; 372:136. [PubMed: 18023836]
43. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. *PLoS pathogens*. 2009; 5:e1000330. [PubMed: 19266078]
44. Li J, Chen Y, Li M, Carpenter MA, McDougale RM, Luengas EM, Macdonald PJ, Harris RS, Mueller JD. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. *Journal of molecular biology*. 2014; 426:1296. [PubMed: 24361275]
45. Nair S, Sanchez-Martinez S, Ji X, Rein A. Biochemical and biological studies of mouse APOBEC3. *Journal of virology*. 2014; 88:3850. [PubMed: 24453360]
46. Wedekind JE, Gillilan R, Janda A, Krucinska J, Salter JD, Bennett RP, Raina J, Smith HC. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. *The Journal of biological chemistry*. 2006; 281:38122. [PubMed: 17079235]
47. Siriwardena SU, Guruge TA, Bhagwat AS. Characterization of the Catalytic Domain of Human APOBEC3B and the Critical Structural Role for a Conserved Methionine. *Journal of molecular biology*. 2015; 427:3042. [PubMed: 26281709]
48. Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. *Molecular cell*. 2002; 10:1247. [PubMed: 12453430]

49. Hodges P, Scott J. Apolipoprotein B mRNA editing: a new tier for the control of gene expression. *Trends in biochemical sciences*. 1992; 17:77. [PubMed: 1373530]
50. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell*. 2000; 102:553. [PubMed: 11007474]
51. Stavrou S, Ross SR. APOBEC3 Proteins in Viral Immunity. *Journal of immunology*. 2015; 195:4565.
52. Willems L, Gillet NA. APOBEC3 Interference during Replication of Viral Genomes. *Viruses*. 2015; 7:2999. [PubMed: 26110583]
53. Burnet FM. A Modification of Jerne's Theory of Antibody Production using the Concept of Clonal Selection. *Aust J Sci*. 1957; 20:67.
54. Burnet, FM. *The Clonal Selection Theory of Acquired Immunity*. Cambridge University Press; Cambridge, England: 1959.
55. Talmage DW. Allergy and immunology. *Annual review of medicine*. 1957; 8:239.
56. Rajewsky K. Clonal selection and learning in the antibody system. *Nature*. 1996; 381:751. [PubMed: 8657279]
57. Victora GD, Mesin L. Clonal and cellular dynamics in germinal centers. *Current opinion in immunology*. 2014; 28:90. [PubMed: 24681449]
58. Victora GD, Nussenzweig MC. Germinal centers. *Annual review of immunology*. 2012; 30:429.
59. Maizels, N., Scharff, MD. *Molecular Biology of B Cells*. Honjo, T, Alt, FW., Neuberger, MS., editors. Elsevier Academic Press; London: 2004.
60. Arakawa H, Hauschild J, Buerstedde JM. Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. *Science (New York, NY)*. 2002; 295:1301.
61. Harris RS, Sale JE, Petersen-Mahrt SK, Neuberger MS. AID is essential for immunoglobulin V gene conversion in a cultured B cell line. *Current biology: CB*. 2002; 12:435. [PubMed: 11882297]
62. Rogozin IB, Kolchanov NA. Somatic hypermutagenesis in immunoglobulin genes. II. Influence of neighbouring base sequences on mutagenesis. *Biochim Biophys Acta*. 1992; 1171:11. [PubMed: 1420357]
63. Rogozin IB, Basu MK, Jordan IK, Pavlov YI, Koonin EV. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. *Cell cycle (Georgetown, Tex)*. 2005; 4:1281.
64. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates *E. coli* suggesting a DNA deamination mechanism for antibody diversification. *Nature*. 2002; 418:99. [PubMed: 12097915]
65. Masutani C, Kusumoto R, Iwai S, Hanaoka F. Mechanisms of accurate translesion synthesis by human DNA polymerase η . *The EMBO journal*. 2000; 19:3100. [PubMed: 10856253]
66. Lawrence CW, Hinkle DC. DNA polymerase ζ and the control of DNA damage induced mutagenesis in eukaryotes. *Cancer surveys*. 1996; 28:21. [PubMed: 8977026]
67. Prakash S, Johnson RE, Prakash L. Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. *Annual review of biochemistry*. 2005; 74:317.
68. Rada C, Di Noia JM, Neuberger MS. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. *Molecular cell*. 2004; 16:163. [PubMed: 15494304]
69. Shen HM, Tanaka A, Bozek G, Nicolae D, Storb U. Somatic hypermutation and class switch recombination in *Msh6(-/-)Ung(-/-)* double-knockout mice. *Journal of immunology*. 2006; 177:5386.
70. Casali P, Pal Z, Xu Z, Zan H. DNA repair in antibody somatic hypermutation. *Trends in immunology*. 2006; 27:313. [PubMed: 16737852]
71. Neuberger MS, Rada C. Somatic hypermutation: activation-induced deaminase for C/G followed by polymerase η for A/T. *The Journal of experimental medicine*. 2007; 204:7. [PubMed: 17190841]
72. Zanotti KJ, Gearhart PJ. Antibody diversification caused by disrupted mismatch repair and promiscuous DNA polymerases. *DNA repair*. 2015; doi: 10.1016/j.dnarep.2015.11.011

73. Peters A, Storb U. Somatic hypermutation of immunoglobulin genes is linked to transcription initiation. *Immunity*. 1996; 4:57. [PubMed: 8574852]
74. Storb U. The molecular basis of somatic hypermutation of immunoglobulin genes. *Current opinion in immunology*. 1996; 8:206. [PubMed: 8725944]
75. Jinks-Robertson S, Bhagwat AS. Transcription-associated mutagenesis. *Annual review of genetics*. 2014; 48:341.
76. Mak CH, Pham P, Afif SA, Goodman MF. A mathematical model for scanning and catalysis on single-stranded DNA, illustrated with activation-induced deoxycytidine deaminase. *The Journal of biological chemistry*. 2013; 288:29786. [PubMed: 23979486]
77. Mak CH, Pham P, Afif SA, Goodman MF. Random-walk enzymes. *Physical review. E, Statistical, nonlinear, and soft matter physics*. 2015; 92:032717.
78. Pham P, Calabrese P, Park SJ, Goodman MF. Analysis of a single-stranded DNA-scanning process in which activation-induced deoxycytidine deaminase (AID) deaminates C to U haphazardly and inefficiently to ensure mutational diversity. *The Journal of biological chemistry*. 2011; 286:24931. [PubMed: 21572036]
79. Bhagwat AS. DNA-cytosine deaminases: from antibody maturation to antiviral defense. *DNA repair*. 2004; 3:85. [PubMed: 14697763]
80. Canugovi C, Samaranyake M, Bhagwat AS. Transcriptional pausing and stalling causes multiple clustered mutations by human activation-induced deaminase. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2009; 23:34. [PubMed: 18772346]
81. Gnatt AL, Cramer P, Fu J, Bushnell DA, Kornberg RD. Structural basis of transcription: an RNA polymerase II elongation complex at 3.3 Å resolution. *Science (New York, NY)*. 2001; 292:1876.
82. Basu U, Meng FL, Keim C, Grinstein V, Pefanis E, Eccleston J, Zhang T, Myers D, Wasserman CR, Wesemann DR, et al. The RNA exosome targets the AID cytidine deaminase to both strands of transcribed duplex DNA substrates. *Cell*. 2011; 144:353. [PubMed: 21255825]
83. Pefanis E, Basu U. RNA Exosome Regulates AID DNA Mutator Activity in the B Cell Genome. *Advances in immunology*. 2015; 127:257. [PubMed: 26073986]
84. Pefanis E, Wang J, Rothschild G, Lim J, Chao J, Rabadan R, Economides AN, Basu U. Noncoding RNA transcription targets AID to divergently transcribed loci in B cells. *Nature*. 2014; 514:389. [PubMed: 25119026]
85. Wright BE, Schmidt KH, Davis N, Hunt AT, Minnick MFII. Correlations between secondary structure stability and mutation frequency during somatic hypermutation. *Molecular immunology*. 2008; 45:3600. [PubMed: 18584870]
86. Wright BE, Schmidt KH, Minnick MF, Davis NI. VH gene transcription creates stabilized secondary structures for coordinated mutagenesis during somatic hypermutation. *Molecular immunology*. 2008; 45:3589. [PubMed: 18585784]
87. Shen HM, Storb U. Activation-induced cytidine deaminase (AID) can target both DNA strands when the DNA is supercoiled. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101:12997. [PubMed: 15328407]
88. Casellas R, Basu U, Yewdell WT, Chaudhuri J, Robbiani DF, Di Noia JM. Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity. *Nat Rev Immunol*. 2016; 16:164. [PubMed: 26898111]
89. Senavirathne G, Bertram JG, Jaszczur M, Chaurasiya KR, Pham P, Mak CH, Goodman MF, Rueda D. Activation-induced deoxycytidine deaminase (AID) co-transcriptional scanning at single-molecule resolution. *Nature communications*. 2015; 6:10209.
90. Rada C, Williams GT, Nilsen H, Barnes DE, Lindahl T, Neuberger MS. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. *Current biology: CB*. 2002; 12:1748. [PubMed: 12401169]
91. Phung QH, Winter DB, Cranston A, Tarone RE, Bohr VA, Fishel R, Gearhart PJ. Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. *The Journal of experimental medicine*. 1998; 187:1745. [PubMed: 9607916]

92. Maul RW, Saribasak H, Martomo SA, McClure RL, Yang W, Vaisman A, Gramlich HS, Schatz DG, Woodgate R, Wilson DM 3rd, et al. Uracil residues dependent on the deaminase AID in immunoglobulin gene variable and switch regions. *Nature immunology*. 2011; 12:70. [PubMed: 21151102]
93. Roche B, Claes A, Rougeon F. Deoxyuridine triphosphate incorporation during somatic hypermutation of mouse V κ Ox genes after immunization with phenylloxazolone. *Journal of immunology*. 2010; 185:4777.
94. Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS. Genomic uracil homeostasis during normal B cell maturation and loss of this balance during B cell cancer development. *Molecular and cellular biology*. 2014; 34:4019. [PubMed: 25154417]
95. Mashiyama ST, Hansen CM, Roitman E, Sarmiento S, Leklem JE, Shultz TD, Ames BN. An assay for uracil in human DNA at baseline: effect of marginal vitamin B6 deficiency. *Analytical biochemistry*. 2008; 372:21. [PubMed: 17963712]
96. Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. *Annual review of immunology*. 2008; 26:261.
97. Stavnezer J, Schrader CE. IgH chain class switch recombination: mechanism and regulation. *Journal of immunology*. 2014; 193:5370.
98. Schrader CE, Linehan EK, Mochevova SN, Woodland RT, Stavnezer J. Inducible DNA breaks in Ig S regions are dependent on AID and UNG. *The Journal of experimental medicine*. 2005; 202:561. [PubMed: 16103411]
99. Ehrenstein MR, Neuberger MS. Deficiency in Msh2 affects the efficiency and local sequence specificity of immunoglobulin class-switch recombination: parallels with somatic hypermutation. *The EMBO journal*. 1999; 18:3484. [PubMed: 10369687]
100. Schrader CE, Edelmann W, Kucherlapati R, Stavnezer J. Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes. *The Journal of experimental medicine*. 1999; 190:323. [PubMed: 10430621]
101. Masani S, Han L, Yu K. Apurinic/apyrimidinic endonuclease 1 is the essential nuclease during immunoglobulin class switch recombination. *Molecular and cellular biology*. 2013; 33:1468. [PubMed: 23382073]
102. Lindahl T. Instability and decay of the primary structure of DNA. *Nature*. 1993; 362:709. [PubMed: 8469282]
103. Pena-Diaz J, Bregenhorn S, Ghodgaonkar M, Follonier C, Artola-Boran M, Castor D, Lopes M, Sartori AA, Jiricny J. Noncanonical mismatch repair as a source of genomic instability in human cells. *Molecular cell*. 2012; 47:669. [PubMed: 22864113]
104. Bregenhorn S, Kallenberger L, Artola-Boran M, Pena-Diaz J, Jiricny J. Non-canonical uracil processing in DNA gives rise to double-strand breaks and deletions: relevance to class switch recombination. *Nucleic Acids Res*. 2016; doi: 10.1093/nar/gkv1535
105. Hasham MG, Snow KJ, Donghia NM, Branca JA, Lessard MD, Stavnezer J, Shopland LS, Mills KD. Activation-induced cytidine deaminase-initiated off-target DNA breaks are detected and resolved during S phase. *Journal of immunology*. 2012; 189:2374.
106. Dunnick W, Hertz GZ, Scappino L, Gritzmacher C. DNA sequences at immunoglobulin switch region recombination sites. *Nucleic Acids Res*. 1993; 21:365. [PubMed: 8441648]
107. Nagaoka H, Muramatsu M, Yamamura N, Kinoshita K, Honjo T. Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin S μ region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. *The Journal of experimental medicine*. 2002; 195:529. [PubMed: 11854365]
108. Xue K, Rada C, Neuberger MS. The in vivo pattern of AID targeting to immunoglobulin switch regions deduced from mutation spectra in msh2 $^{-/-}$ ung $^{-/-}$ mice. *The Journal of experimental medicine*. 2006; 203:2085. [PubMed: 16894013]
109. Morgan HD, Santos F, Green K, Dean W, Reik W. Epigenetic reprogramming in mammals. *Human molecular genetics*. 2005; 14(Spec No 1):R47. [PubMed: 15809273]
110. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. *Nature*. 2007; 447:425. [PubMed: 17522676]

111. Morgan HD, Dean W, Coker HA, Reik W, Petersen-Mahrt SK. Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. *The Journal of biological chemistry*. 2004; 279:52353. [PubMed: 15448152]
112. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. *The Journal of biological chemistry*. 1999; 274:18470. [PubMed: 10373455]
113. Larijani M, Frieder D, Sonbuchner TM, Bransteitter R, Goodman MF, Bouhassira EE, Scharff MD, Martin A. Methylation protects cytidines from AID-mediated deamination. *Molecular immunology*. 2005; 42:599. [PubMed: 15607819]
114. Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang Y, Kohli RM. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. *Nature chemical biology*. 2012; 8:751. [PubMed: 22772155]
115. Rangam G, Schmitz KM, Cobb AJ, Petersen-Mahrt SK. AID enzymatic activity is inversely proportional to the size of cytosine C5 orbital cloud. *PloS one*. 2012; 7:e43279. [PubMed: 22916236]
116. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. *Science (New York, NY)*. 2011; 333:1300.
117. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science (New York, NY)*. 2009; 324:930.
118. Gkoutela S, Clark AT. A big surprise in the little zygote: the curious business of losing methylated cytosines. *Cell stem cell*. 2014; 15:393. [PubMed: 25280211]
119. Nabel CS, Manning SA, Kohli RM. The curious chemical biology of cytosine: deamination, methylation, and oxidation as modulators of genomic potential. *ACS chemical biology*. 2012; 7:20. [PubMed: 22004246]
120. Fritz EL, Rosenberg BR, Lay K, Mihailovic A, Tuschl T, Papavasiliou FN. A comprehensive analysis of the effects of the deaminase AID on the transcriptome and methylome of activated B cells. *Nature immunology*. 2013; 14:749. [PubMed: 23708250]
121. Bhutani N, Decker MN, Brady JJ, Bussat RT, Burns DM, Corbel SY, Blau HM. A critical role for AID in the initiation of reprogramming to induced pluripotent stem cells. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2013; 27:1107. [PubMed: 23212122]
122. Dominguez PM, Teater M, Chambwe N, Kormaksson M, Redmond D, Ishii J, Vuong B, Chaudhuri J, Melnick A, Vasanthakumar A, et al. DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. *Cell reports*. 2015; 12:2086. [PubMed: 26365193]
123. Kumar R, DiMenna L, Schrode N, Liu TC, Franck P, Munoz-Descalzo S, Hadjantonakis AK, Zarrin AA, Chaudhuri J, Elemento O, et al. AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes. *Nature*. 2013; 500:89. [PubMed: 23803762]
124. Munoz DP, Lee EL, Takayama S, Coppe JP, Heo SJ, Boffelli D, Di Noia JM, Martin DI. Activation-induced cytidine deaminase (AID) is necessary for the epithelial-mesenchymal transition in mammary epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110:E2977. [PubMed: 23882083]
125. Ramiro AR, Barreto VM. Activation-induced cytidine deaminase and active cytidine demethylation. *Trends in biochemical sciences*. 2015; 40:172. [PubMed: 25661247]
126. Nambu Y, Sugai M, Gonda H, Lee CG, Kataikai T, Agata Y, Yokota Y, Shimizu A. Transcription-coupled events associating with immunoglobulin switch region chromatin. *Science (New York, NY)*. 2003; 302:2137.
127. Yamane A, Resch W, Kuo N, Kuchen S, Li Z, Sun HW, Robbiani DF, McBride K, Nussenzweig MC, Casellas R. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. *Nature immunology*. 2011; 12:62. [PubMed: 21113164]

128. Liu M, Duke JL, Richter DJ, Vinuesa CG, Goodnow CC, Kleinstein SH, Schatz DG. Two levels of protection for the B cell genome during somatic hypermutation. *Nature*. 2008; 451:841. [PubMed: 18273020]
129. Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho YJ, Myers DR, Choi VW, Compagno M, Malkin DJ, et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. *Cell*. 2011; 147:107. [PubMed: 21962511]
130. Klein IA, Resch W, Jankovic M, Oliveira T, Yamane A, Nakahashi H, Di Virgilio M, Bothmer A, Nussenzweig A, Robbiani DF, et al. Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. *Cell*. 2011; 147:95. [PubMed: 21962510]
131. Greeve J, Philipsen A, Krause K, Klapper W, Heidorn K, Castle BE, Janda J, Marcu KB, Parwaresch R. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. *Blood*. 2003; 101:3574. [PubMed: 12511417]
132. Hardianti MS, Tatsumi E, Syampurnawati M, Furuta K, Saigo K, Nakamachi Y, Kumagai S, Ohno H, Tanabe S, Uchida M, et al. Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL. *Leukemia*. 2004; 18:826. [PubMed: 14990977]
133. Lossos IS, Levy R, Alizadeh AA. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. *Leukemia*. 2004; 18:1775. [PubMed: 15385936]
134. Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R, Chaganti RS, Dalla-Favera R. Expression of the AID protein in normal and neoplastic B cells. *Blood*. 2004; 104:3318. [PubMed: 15304391]
135. Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. *Cancer research*. 2003; 63:3894. [PubMed: 12873980]
136. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. *Oncogene*. 2001; 20:5580. [PubMed: 11607811]
137. Rabbitts TH. Chromosomal translocations in human cancer. *Nature*. 1994; 372:143. [PubMed: 7969446]
138. Gazumyan A, Bothmer A, Klein IA, Nussenzweig MC, McBride KM. Activation-induced cytidine deaminase in antibody diversification and chromosome translocation. *Advances in cancer research*. 2012; 113:167. [PubMed: 22429855]
139. Gostissa M, Alt FW, Chiarle R. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. *Annual review of immunology*. 2011; 29:319.
140. Robbiani, DF., Nussenzweig, MC. *Annual Review of Pathology: Mechanisms of Disease*, Vol 8. Abbas, AK, Galli, SJ., Howley, PM., editors. Vol. 8. 2013.
141. Potter M. Neoplastic development in plasma cells. *Immunological reviews*. 2003; 194:177. [PubMed: 12846815]
142. Potter M, Wiener F. Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. *Carcinogenesis*. 1992; 13:1681. [PubMed: 1423827]
143. Ramiro AR, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M, Honjo T, Nussenzweig A, Nussenzweig MC. AID is required for c-myc/IgH chromosome translocations in vivo. *Cell*. 2004; 118:431. [PubMed: 15315756]
144. Robbiani DF, Bothmer A, Callen E, Reina-San-Martin B, Dorsett Y, Difilippantonio S, Bolland DJ, Chen HT, Corcoran AE, Nussenzweig A, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. *Cell*. 2008; 135:1028. [PubMed: 19070574]
145. Pasqualucci L, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, Honjo T, Morse HC 3rd, Nussenzweig MC, Dalla-Favera R. AID is required for germinal center-derived lymphomagenesis. *Nature genetics*. 2008; 40:108. [PubMed: 18066064]
146. Komeno Y, Kitaura J, Watanabe-Okochi N, Kato N, Oki T, Nakahara F, Harada Y, Harada H, Shinkura R, Nagaoka H, et al. AID-induced T-lymphoma or B-leukemia/lymphoma in a mouse BMT model. *Leukemia*. 2010; 24:1018. [PubMed: 20357822]

147. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T. Constitutive expression of AID leads to tumorigenesis. *The Journal of experimental medicine*. 2003; 197:1173. [PubMed: 12732658]
148. Okazaki IM, Kotani A, Honjo T. Role of AID in tumorigenesis. *Advances in immunology*. 2007; 94:245. [PubMed: 17560277]
149. Kotani A, Okazaki IM, Muramatsu M, Kinoshita K, Begum NA, Nakajima T, Saito H, Honjo T. A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:4506. [PubMed: 15767564]
150. Hatada EN, Krappmann D, Scheidereit C. NF-kappaB and the innate immune response. *Current opinion in immunology*. 2000; 12:52. [PubMed: 10679399]
151. Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. *Microbiology and molecular biology reviews: MMBR*. 2001; 65:131. [PubMed: 11238989]
152. Jiang C, Foley J, Clayton N, Kissling G, Jokinen M, Herbert R, Diaz M. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. *Journal of immunology*. 2007; 178:7422.
153. Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, Watashi K, Shimotohno K, Honjo T, Chiba T. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. *Oncogene*. 2007; 26:5587. [PubMed: 17404578]
154. Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T, et al. Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). *The Journal of biological chemistry*. 2013; 288:31715. [PubMed: 24025329]
155. Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T, Kinoshita K, Honjo T, Chiba T. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. *Gastroenterology*. 2008; 135:889. [PubMed: 18691581]
156. Dedeoglu F, Horwitz B, Chaudhuri J, Alt FW, Geha RS. Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB. *International immunology*. 2004; 16:395. [PubMed: 14978013]
157. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, Catalan N, Forveille M, Dufourcq-Labeuise R, Gennery A, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). *Cell*. 2000; 102:565. [PubMed: 11007475]
158. Quartier P, Bustamante J, Sanal O, Plebani A, Debre M, Deville A, Litzman J, Levy J, Fermanet JP, Lane P, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. *Clin Immunol*. 2004; 110:22. [PubMed: 14962793]
159. Meyers G, Ng YS, Bannock JM, Lavoie A, Walter JE, Notarangelo LD, Kilic SS, Aksu G, Debre M, Rieux-Laucat F, et al. Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:11554. [PubMed: 21700883]
160. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. *Science (New York, NY)*. 2003; 301:1374.
161. Cantaert T, Schickel JN, Bannock JM, Ng YS, Massad C, Oe T, Wu R, Lavoie A, Walter JE, Notarangelo LD, et al. Activation-Induced Cytidine Deaminase Expression in Human B Cell Precursors Is Essential for Central B Cell Tolerance. *Immunity*. 2015; 43:884. [PubMed: 26546282]
162. Kuraoka M, Holl TM, Liao D, Womble M, Cain DW, Reynolds AE, Kelsoe G. Activation-induced cytidine deaminase mediates central tolerance in B cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:11560. [PubMed: 21700885]
163. Rosenspire AJ, Chen K. Anergic B Cells: Precarious On-Call Warriors at the Nexus of Autoimmunity and False-Flagged Pathogens. *Front Immunol*. 2015; 6:580. [PubMed: 26635794]

164. Chen L, Guo L, Tian J, Zheng B, Han S. Deficiency in activation-induced cytidine deaminase promotes systemic autoimmunity in lpr mice on a C57BL/6 background. *Clin Exp Immunol*. 2010; 159:169. [PubMed: 19922498]
165. Hase K, Takahashi D, Ebisawa M, Kawano S, Itoh K, Ohno H. Activation-induced cytidine deaminase deficiency causes organ-specific autoimmune disease. *PloS one*. 2008; 3:e3033. [PubMed: 18716662]
166. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. *Nat Rev Immunol*. 2009; 9:845. [PubMed: 19935804]
167. Xu X, Hsu HC, Chen J, Grizzle WE, Chatham WW, Stockard CR, Wu Q, Yang PA, Holers VM, Mountz JD. Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis. *Scand J Immunol*. 2009; 70:309. [PubMed: 19703021]
168. Hsu HC, Wu Y, Yang P, Wu Q, Job G, Chen J, Wang J, Accavitti-Loper MA, Grizzle WE, Carter RH, et al. Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. *Journal of immunology*. 2007; 178:5357.
169. Guo W, Smith D, Aviszus K, Detanico T, Heiser RA, Wysocki LJ. Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. *The Journal of experimental medicine*. 2010; 207:2225. [PubMed: 20805563]
170. Jiang C, Zhao ML, Diaz M. Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis. *Immunology*. 2009; 126:102. [PubMed: 18624728]
171. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. *The Journal of experimental medicine*. 1999; 189:1639. [PubMed: 10330443]
172. Qin H, Suzuki K, Nakata M, Chikuma S, Izumi N, Huong le T, Maruya M, Fagarasan S, Busslinger M, Honjo T, et al. Activation-induced cytidine deaminase expression in CD4+ T cells is associated with a unique IL-10-producing subset that increases with age. *PloS one*. 2011; 6:e29141. [PubMed: 22216188]
173. Bacchetta R, Notarangelo LD. Immunodeficiency with autoimmunity: beyond the paradox. *Front Immunol*. 2013; 4:77. [PubMed: 23630524]
174. Qian X, Balestra ME, Yamanaka S, Boren J, Lee I, Innerarity TL. Low expression of the apolipoprotein B mRNA-editing transgene in mice reduces LDL levels but does not cause liver dysplasia or tumors. *Arteriosclerosis, thrombosis, and vascular biology*. 1998; 18:1013.
175. Innerarity TL, Boren J, Yamanaka S, Olofsson SO. Biosynthesis of apolipoprotein B48-containing lipoproteins. Regulation by novel post-transcriptional mechanisms. *The Journal of biological chemistry*. 1996; 271:2353. [PubMed: 8576187]
176. Lellek H, Kirsten R, Diehl I, Apostel F, Buck F, Greeve J. Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex. *The Journal of biological chemistry*. 2000; 275:19848. [PubMed: 10781591]
177. Mehta A, Kinter MT, Sherman NE, Driscoll DM. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. *Molecular and cellular biology*. 2000; 20:1846. [PubMed: 10669759]
178. Navaratnam N, Morrison JR, Bhattacharya S, Patel D, Funahashi T, Giannoni F, Teng BB, Davidson NO, Scott J. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. *The Journal of biological chemistry*. 1993; 268:20709. [PubMed: 8407891]
179. Yamanaka S, Poksay KS, Arnold KS, Innerarity TL. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. *Genes & development*. 1997; 11:321. [PubMed: 9030685]
180. Rosenberg BR, Hamilton CE, Mwangi MM, Dewell S, Papavasiliou FN. Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs. *Nature structural & molecular biology*. 2011; 18:230.
181. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in

transgenic animals. *Proceedings of the National Academy of Sciences of the United States of America*. 1995; 92:8483. [PubMed: 7667315]

182. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. *Cell*. 2003; 114:21. [PubMed: 12859895]
183. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. *Nucleic Acids Res*. 2010; 38:4274. [PubMed: 20308164]
184. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. *Journal of virology*. 2009; 83:9474. [PubMed: 19587057]
185. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. *The Journal of experimental medicine*. 2006; 203:41. [PubMed: 16418394]
186. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. *Journal of virology*. 2006; 80:7645. [PubMed: 16840343]
187. Wang FX, Huang J, Zhang H, Ma X, Zhang H. APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells. *The Journal of general virology*. 2008; 89:722. [PubMed: 18272764]
188. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. *The Journal of biological chemistry*. 2007; 282:3539. [PubMed: 17110377]
189. Argyris EG, Acheampong E, Wang F, Huang J, Chen K, Mukhtar M, Zhang H. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. *Virology*. 2007; 367:440. [PubMed: 17631933]
190. Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, Kodama Y, Endo Y, Yamauchi J, Matsumoto T, Takaori-Kondo A, et al. Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. *Biochemical and biophysical research communications*. 2006; 341:314. [PubMed: 16426578]
191. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson S, Vartanian JP, et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. *Hepatology (Baltimore, Md)*. 2006; 43:1364.
192. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. *Science (New York, NY)*. 2014; 343:1221.
193. Wang Z, Wakae K, Kitamura K, Aoyama S, Liu G, Koura M, Monjurul AM, Kukimoto I, Muramatsu M. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. *Journal of virology*. 2014; 88:1308. [PubMed: 24227842]
194. Medzhitov R. Recognition of microorganisms and activation of the immune response. *Nature*. 2007; 449:819. [PubMed: 17943118]
195. Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. *Nature immunology*. 2009; 10:266. [PubMed: 19158679]
196. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. *Nat Rev Immunol*. 2008; 8:559. [PubMed: 18575461]
197. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. *Nature*. 2007; 448:501. [PubMed: 17618271]

198. Barber GN. Cytoplasmic DNA innate immune pathways. *Immunological reviews*. 2011; 243:99. [PubMed: 21884170]
199. Barber GN. STING: infection, inflammation and cancer. *Nat Rev Immunol*. 2015; 15:760. [PubMed: 26603901]
200. Radoshevich L, Dussurget O. Cytosolic Innate Immune Sensing and Signaling upon Infection. *Frontiers in microbiology*. 2016; 7:313. [PubMed: 27014235]
201. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. *Nature structural & molecular biology*. 2010; 17:222.
202. Land AM, Law EK, Carpenter MA, Lackey L, Brown WL, Harris RS. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. *The Journal of biological chemistry*. 2013; 288:17253. [PubMed: 23640892]
203. Pham P, Landolph A, Mendez C, Li N, Goodman MF. A biochemical analysis linking APOBEC3A to disparate HIV-1 restriction and skin cancer. *The Journal of biological chemistry*. 2013; 288:29294. [PubMed: 23979356]
204. Messina JP, Gilkeson GS, Pisetsky DS. The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. *Cellular immunology*. 1993; 147:148. [PubMed: 8462107]
205. Carpenter MA, Li M, Rathore A, Lackey L, Law EK, Land AM, Leonard B, Shandilya SM, Bohn MF, Schiffer CA, et al. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. *The Journal of biological chemistry*. 2012; 287:34801. [PubMed: 22896697]
206. Suspene R, Aynaud MM, Vartanian JP, Wain-Hobson S. Efficient deamination of 5-methylcytidine and 5-substituted cytidine residues in DNA by human APOBEC3A cytidine deaminase. *PloS one*. 2013; 8:e63461. [PubMed: 23840298]
207. Hoelzer K, Shackelton LA, Parrish CR. Presence and role of cytosine methylation in DNA viruses of animals. *Nucleic Acids Res*. 2008; 36:2825. [PubMed: 18367473]
208. Vieira VC, Soares MA. The role of cytidine deaminases on innate immune responses against human viral infections. *BioMed research international*. 2013; 2013:683095. [PubMed: 23865062]
209. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature*. 2002; 418:646. [PubMed: 12167863]
210. Desimie BA, Delviks-Frankenberry KA, Burdick RC, Qi D, Izumi T, Pathak VK. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. *Journal of molecular biology*. 2014; 426:1220. [PubMed: 24189052]
211. Harris RS, Dudley JP. APOBECs and virus restriction. *Virology*. 2015; 479–480:131.
212. Moris A, Murray S, Cardinaud S. AID and APOBECs span the gap between innate and adaptive immunity. *Frontiers in microbiology*. 2014; 5:534. [PubMed: 25352838]
213. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. *Nature*. 2003; 424:99. [PubMed: 12808466]
214. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. *Nature*. 2003; 424:94. [PubMed: 12808465]
215. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. *Retrovirology*. 2008; 5:51. [PubMed: 18577210]
216. Krokan HE, Drablos F, Slupphaug G. Uracil in DNA—occurrence, consequences and repair. *Oncogene*. 2002; 21:8935. [PubMed: 12483510]
217. Conticello SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. *Current biology: CB*. 2003; 13:2009. [PubMed: 14614829]
218. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. *Nature medicine*. 2003; 9:1404.
219. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. *Science (New York, NY)*. 2003; 302:1056.

220. Aydin H, Taylor MW, Lee JE. Structure-guided analysis of the human APOBEC3-HIV restrictome. *Structure* (London, England: 1993). 2014; 22:668.
221. Feng Y, Baig TT, Love RP, Chelico L. Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. *Frontiers in microbiology*. 2014; 5:450. [PubMed: 25206352]
222. Kim DY. The assembly of Vif ubiquitin E3 ligase for APOBEC3 degradation. *Archives of pharmacol research*. 2015; 38:435. [PubMed: 25408426]
223. Salter JD, Morales GA, Smith HC. Structural insights for HIV-1 therapeutic strategies targeting Vif. *Trends in biochemical sciences*. 2014; 39:373. [PubMed: 25124760]
224. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. *Journal of virology*. 2011; 85:11220. [PubMed: 21835787]
225. Sato K, Takeuchi JS, Misawa N, Izumi T, Kobayashi T, Kimura Y, Iwami S, Takaori-Kondo A, Hu WS, Aihara K, et al. APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. *PLoS pathogens*. 2014; 10:e1004453. [PubMed: 25330146]
226. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, Muriaux D, Darlix JL, Cimorelli A. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. *PLoS pathogens*. 2011; 7:e1002221. [PubMed: 21966267]
227. Doehle BP, Schafer A, Cullen BR. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. *Virology*. 2005; 339:281. [PubMed: 15993456]
228. Itaya S, Nakajima T, Kaur G, Terunuma H, Ohtani H, Mehra N, Kimura A. No evidence of an association between the APOBEC3B deletion polymorphism and susceptibility to HIV infection and AIDS in Japanese and Indian populations. *The Journal of infectious diseases*. 2010; 202:815. [PubMed: 20684727]
229. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. *The Journal of biological chemistry*. 2004; 279:53379. [PubMed: 15466872]
230. Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, Malim MH. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. *Journal of virology*. 2013; 87:1508. [PubMed: 23152537]
231. Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T. APOBEC3G targets human T-cell leukemia virus type 1. *Retrovirology*. 2005; 2:32. [PubMed: 15943885]
232. Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, Vartanian JP, Matsuoka M. APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. *Journal of virology*. 2010; 84:7278. [PubMed: 20463074]
233. Ooms M, Krikoni A, Kress AK, Simon V, Munk C. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. *Journal of virology*. 2012; 86:6097. [PubMed: 22457529]
234. Delebecque F, Suspene R, Calattini S, Casartelli N, Saib A, Froment A, Wain-Hobson S, Gessain A, Vartanian JP, Schwartz O. Restriction of foamy viruses by APOBEC cytidine deaminases. *Journal of virology*. 2006; 80:605. [PubMed: 16378963]
235. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:2915. [PubMed: 17299050]
236. Oguariri RM, Dai L, Adelsberger JW, Rupert A, Stevens R, Yang J, Huang D, Lempicki RA, Zhou M, Baseler MW, et al. Interleukin-2 inhibits HIV-1 replication in some human T cell lymphotropic virus-1-infected cell lines via the induction and incorporation of APOBEC3G into the virion. *The Journal of biological chemistry*. 2013; 288:17812. [PubMed: 23640893]
237. Ohsugi T, Koito A. Human T cell leukemia virus type I is resistant to the antiviral effects of APOBEC3. *Journal of virological methods*. 2007; 139:93. [PubMed: 17123636]

238. Russell RA, Wiegand HL, Moore MD, Schafer A, McClure MO, Cullen BR. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. *Journal of virology*. 2005; 79:8724. [PubMed: 15994766]
239. Janahi EM, McGarvey MJ. The inhibition of hepatitis B virus by APOBEC cytidine deaminases. *Journal of viral hepatitis*. 2013; 20:821. [PubMed: 24304451]
240. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. *Current biology: CB*. 2006; 16:480. [PubMed: 16527742]
241. Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, Logue E, Landau NR, Weitzman MD. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. *PLoS pathogens*. 2009; 5:e1000439. [PubMed: 19461882]
242. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:8321. [PubMed: 15919829]
243. He X, Li J, Wu J, Zhang M, Gao P. Associations between activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review). *Molecular medicine reports*. 2015; 12:6405. [PubMed: 26398702]
244. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, Lee D, Soares MA, Lambert PF, Howley PM, et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. *mBio*. 2014; 5
245. Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. *Science (New York, NY)*. 2008; 320:230.
246. Suspene R, Aynaud MM, Koch S, Padeloup D, Labetoulle M, Gaertner B, Vartanian JP, Meyerhans A, Wain-Hobson S. Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. *Journal of virology*. 2011; 85:7594. [PubMed: 21632763]
247. Minkah N, Macaluso M, Oldenburg DG, Paden CR, White DW, McBride KM, Krug LT. Absence of the uracil DNA glycosylase of murine gammaherpesvirus 68 impairs replication and delays the establishment of latency in vivo. *Journal of virology*. 2015; 89:3366. [PubMed: 25589640]
248. Pyles RB, Thompson RL. Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. *Journal of virology*. 1994; 68:4963. [PubMed: 8035495]
249. Su MT, Liu IH, Wu CW, Chang SM, Tsai CH, Yang PW, Chuang YC, Lee CP, Chen MR. Uracil DNA glycosylase BKRF3 contributes to Epstein-Barr virus DNA replication through physical interactions with proteins in viral DNA replication complex. *Journal of virology*. 2014; 88:8883. [PubMed: 24872582]
250. Suspene R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP. Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR. *The Journal of general virology*. 2005; 86:125. [PubMed: 15604439]
251. Suspene R, Caval V, Henry M, Bouzidi MS, Wain-Hobson S, Vartanian JP. Erroneous identification of APOBEC3-edited chromosomal DNA in cancer genomics. *British journal of cancer*. 2014; 110:2615. [PubMed: 24691422]
252. Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, Moran JV, Cullen BR. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. *Proceedings of the National Academy of Sciences of the United States of America*. 2006; 103:8780. [PubMed: 16728505]
253. Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, Cichutek K, Flory E, Schumann GG, Munk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition. *The Journal of biological chemistry*. 2006; 281:22161. [PubMed: 16735504]

254. Richardson SR, Narvaiza I, Planegger RA, Weitzman MD, Moran JV. APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition. *eLife*. 2014; 3:e02008. [PubMed: 24843014]
255. Stenglein MD, Harris RS. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. *The Journal of biological chemistry*. 2006; 281:16837. [PubMed: 16648136]
256. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing? *Trends in biochemical sciences*. 2007; 32:118. [PubMed: 17303427]
257. Koyama T, Arias JF, Iwabu Y, Yokoyama M, Fujita H, Sato H, Tokunaga K. APOBEC3G oligomerization is associated with the inhibition of both Alu and LINE-1 retrotransposition. *PloS one*. 2013; 8:e84228. [PubMed: 24367644]
258. Dutko JA, Schafer A, Kenny AE, Cullen BR, Curcio MJ. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. *Current biology: CB*. 2005; 15:661. [PubMed: 15823539]
259. Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, Hance AJ, Heidmann T, Schwartz O. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. *Nature*. 2005; 433:430. [PubMed: 15674295]
260. Bannert N, Kurth R. Retroelements and the human genome: new perspectives on an old relation. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101(Suppl 2):14572. [PubMed: 15310846]
261. Anwar F, Davenport MP, Ebrahimi D. Footprint of APOBEC3 on the genome of human retroelements. *Journal of virology*. 2013; 87:8195. [PubMed: 23698293]
262. Bailey JA, Liu G, Eichler EE. An Alu transposition model for the origin and expansion of human segmental duplications. *American journal of human genetics*. 2003; 73:823. [PubMed: 14505274]
263. Kim TM, Hong SJ, Rhyu MG. Periodic explosive expansion of human retroelements associated with the evolution of the hominoid primate. *Journal of Korean medical science*. 2004; 19:177. [PubMed: 15082888]
264. Marques AC, Dupanloup I, Vinckenbosch N, Reymond A, Kaessmann H. Emergence of young human genes after a burst of retroposition in primates. *PLoS biology*. 2005; 3:e357. [PubMed: 16201836]
265. Pasqualucci L, Migliazza A, Fracchiolla N, William C, Neri A, Baldini L, Chaganti RS, Klein U, Kuppers R, Rajewsky K, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proceedings of the National Academy of Sciences of the United States of America*. 1998; 95:11816. [PubMed: 9751748]
266. Shen HM, Peters A, Baron B, Zhu X, Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. *Science (New York, NY)*. 1998; 280:1750.
267. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. Signatures of mutational processes in human cancer. *Nature*. 2013; 500:415. [PubMed: 23945592]
268. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, et al. Mutational processes molding the genomes of 21 breast cancers. *Cell*. 2012; 149:979. [PubMed: 22608084]
269. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. *Nature genetics*. 2013; 45:970. [PubMed: 23852170]
270. Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, Klimczak LJ, Kryukov GV, Malc E, Mieczkowski PA, et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. *Molecular cell*. 2012; 46:424. [PubMed: 22607975]
271. Harris RS. Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. *Genome medicine*. 2013; 5:87. [PubMed: 24073723]
272. Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. *Nature reviews. Cancer*. 2014; 14:786. [PubMed: 25568919]

273. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. *Nature*. 2013; 494:366. [PubMed: 23389445]
274. Harris RS. Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. *Breast cancer research: BCR*. 2015; 17:8. [PubMed: 25848704]
275. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. *Cancer discovery*. 2015; 5:704. [PubMed: 26091828]
276. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. *eLife*. 2013; 2:e00534. [PubMed: 23599896]
277. Kuong KJ, Loeb LA. APOBEC3B mutagenesis in cancer. *Nature genetics*. 2013; 45:964. [PubMed: 23985681]
278. Kazanov MD, Roberts SA, Polak P, Stamatoyannopoulos J, Klimczak LJ, Gordenin DA, Sunyaev SR. APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, Gene-Dense, and Active Chromatin Regions. *Cell reports*. 2015; 13:1103. [PubMed: 26527001]
279. Green AM, Landry S, Budagyan K, Avgousti DC, Shalhout S, Bhagwat AS, Weitzman MD. APOBEC3A damages the cellular genome during DNA replication. *Cell cycle (Georgetown, Tex)*. 2016; 15:998.
280. Chan K, Gordenin DA. Clusters of Multiple Mutations: Incidence and Molecular Mechanisms. *Annual review of genetics*. 2015; 49:243.
281. Haradhvala NJ, Polak P, Stojanov P, Covington KR, Shinbrot E, Hess JM, Rheinbay E, Kim J, Maruvka YE, Braunstein LZ, et al. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. *Cell*. 2016; 164:538. [PubMed: 26806129]
282. Seplyarskiy VB, Soldatov RA, Popadin KY, Antonarakis SE, Bazykin GA, Nikolaev SI. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. *Genome research*. 2016; 26:174. [PubMed: 26755635]
283. Langston LD, O'Donnell M. DNA replication: keep moving and don't mind the gap. *Molecular cell*. 2006; 23:155. [PubMed: 16857582]
284. Hoopes JI, Cortez LM, Mertz TM, Malc EP, Mieczkowski PA, Roberts SA. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. *Cell reports*. 2016; doi: 10.1016/j.celrep.2016.01.021
285. Bhagwat AS, Hao W, Townes JP, Lee H, Tang H, Foster PL. Strand-biased cytosine deamination at the replication fork causes cytosine to thymine mutations in *Escherichia coli*. *Proceedings of the National Academy of Sciences of the United States of America*. 2016; doi: 10.1073/pnas.1522325113
286. Chan K, Sterling JF, Roberts SA, Bhagwat AS, Resnick MA, Gordenin DA. Base damage within single-strand DNA underlies in vivo hypermutability induced by a ubiquitous environmental agent. *PLoS genetics*. 2012; 8:e1003149. [PubMed: 23271983]
287. Lada AG, Kliver SF, Dhar A, Polev DE, Masharsky AE, Rogozin IB, Pavlov YI. Disruption of Transcriptional Coactivator Sub1 Leads to Genome-Wide Re-distribution of Clustered Mutations Induced by APOBEC in Active Yeast Genes. *PLoS genetics*. 2015; 11:e1005217. [PubMed: 25941824]
288. Lada AG, Stepchenkova EI, Waisertreiger IS, Noskov VN, Dhar A, Eudy JD, Boissy RJ, Hirano M, Rogozin IB, Pavlov YI. Genome-wide mutation avalanches induced in diploid yeast cells by a base analog or an APOBEC deaminase. *PLoS genetics*. 2013; 9:e1003736. [PubMed: 24039593]
289. Beletskii A, Bhagwat AS. Transcription-induced mutations: increase in C to T mutations in the nontranscribed strand during transcription in *Escherichia coli*. *Proceedings of the National Academy of Sciences of the United States of America*. 1996; 93:13919. [PubMed: 8943036]
290. Parkin DM. The global health burden of infection-associated cancers in the year 2002. *International journal of cancer. Journal international du cancer*. 2006; 118:3030. [PubMed: 16404738]
291. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. *Carcinogenesis*. 2000; 21:405. [PubMed: 10688861]

292. Sarid R, Gao SJ. Viruses and human cancer: from detection to causality. *Cancer letters*. 2011; 305:218. [PubMed: 20971551]
293. Read SA, Douglas MW. Virus induced inflammation and cancer development. *Cancer letters*. 2014; 345:174. [PubMed: 23941825]
294. Chai EZ, Siveen KS, Shanmugam MK, Arfuso F, Sethi G. Analysis of the intricate relationship between chronic inflammation and cancer. *The Biochemical journal*. 2015; 468:1. [PubMed: 25940732]
295. Niavarani A, Currie E, Reyat Y, Anjos-Afonso F, Horswell S, Griessinger E, Luis Sardina J, Bonnet D. APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts. *PloS one*. 2015; 10:e0120089. [PubMed: 25807502]
296. Zheng S, Vuong BQ, Vaidyanathan B, Lin JY, Huang FT, Chaudhuri J. Non-coding RNA Generated following Lariat Debranching Mediates Targeting of AID to DNA. *Cell*. 2015; 161:762. [PubMed: 25957684]
297. Le Q, Maizels N. Cell Cycle Regulates Nuclear Stability of AID and Determines the Cellular Response to AID. *PLoS genetics*. 2015; 11:e1005411. [PubMed: 26355458]

Figure 1.

Structure of AID/APOBEC family proteins. A. Multiple sequence alignment of human APOBEC3 proteins with known crystal structures. ENDscript 2 software was used to generate the sequence alignment of A3A (PDB: 4XX0), A3B-CTD (PDB: 5CQD), A3C (PDB: 3VM8) and A3G-CTD (PDB: 3IR2) using A3F-CTD (PDB: 4IOU) as the query. It is important to note that some of the crystallized proteins had several amino acid substitutions and in cases of proteins with two Zn^{2+} binding domains, only the carboxy-terminal domain (CTD) was crystallized. Residues shown in white against a red background are identical and

similar residues are shown in red against a yellow background. The amino acid residues that constitute the active site are marked with red asterisks and the putative DNA binding region is identified with a dashed red line. Secondary structure elements in all APOBEC3 crystal structures are displayed above the sequence alignment (α helices with squiggles, β strands with arrows and turns with the letter T). Helices are numbered from α 1 through α 6, strands from β 1 through β 5 and loop regions from L1 through L10. B. The Coulombic surface potential of the A3F-CTD structure was generated using UCSF Chimera software. The color code is blue (positive), white (neutral) and red (negative). C280, C283 and H249 residues coordinate Zn ion (magenta). Active site glutamate (E251) is also shown. L7 (yellow) is the putative DNA sequence recognition loop and two possible trajectories for DNA binding are shown as dashed green lines.

Figure 2. Role of AID in antibody maturation. Schematic organization of the murine heavy chain gene (IgH) and its alterations during antibody maturation are shown. Abbreviations- VDJ- Rearranged V, D and J segments; E, enhancer, S, switch region; C, constant region; 3'-RR, regulatory region, Pol II, RNA polymerase II; AID, activation-induced deaminase; UNG2, nuclear form of UNG; AP endonuclease, abasic endonuclease; MMR, mismatch repair; TLS polymerase, translesion synthesis polymerase; NHEJ, non-homologous end-joining; altEJ, alternate end-joining. The subscripts μ , ϵ and α to different constant segments. Representative base substitution mutations within VDJ (SHM) and the μ - ϵ hybrid switch region are shown and the IgM to IgE isotype switch in the antibody is indicated in the figure.

Figure 3.

Consequences of cytosine deamination. **A.** Consequences of cytosine deamination in a transcription bubble. The direction of transcription is shown by an arrow and the mRNA is shown in green. During transcription the cytosines in the non-template strand of the transcription bubble are accessible and may be deaminated by the AID/APOBEC proteins. The resulting uracils may be repaired through error-free base excision repair restoring the C:G pair, copied during replication creating G:C to A:T mutations or undergo error-prone repair resulting in all possible base substitutions. N: any base, N': complement of N. **B.** Consequences of cytosine deamination at a replication fork. A replication fork with cytosines in the leading strand template (LDST) and the lagging strand template (LGST) are shown. The closed arrow-head represents the helicase that opens the DNA and is pointed in the overall direction of replication. AID/APOBEC proteins deaminate cytosines in LGST and the resulting uracils are either copied during replication (upper branch) or undergo repair (lower branch). Replication without repair results in C:G to T:A mutations in the LGST. Alternately, uracil-DNA glycosylase (UNG) may excise the uracils and the resulting abasic sites may be copied by translesion synthesis (TLS) polymerases creating mutations (downward arrow). The predominant mutations caused by polymerases η and REV1 are shown. AP endonuclease may nick the DNA at the abasic site and this will lead to double strand (DS) breaks in DNA and cause replication fork to collapse.

Figure 4. Linking viral infection, AID/APOBEC expression and cancer. During viral infection cytokines (yellow triangles) trigger the expression of AID/APOBEC proteins (purple ovals) via NF- κB pathway. These enzymes damage the viral genome (red star) and promote creation of high affinity antibodies against the virus. This helps the body clear the virus. Additionally, off-target damage to cellular DNA leads to mutations and strand breaks resulting in genome instability. This may lead to cell death or malignant transformation.